

Author Search

=> FILE HCAPLUS

FILE 'HCAPLUS' ENTERED AT 14:57:19 ON 22 MAY 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 May 2009 VOL 150 ISS 22

FILE LAST UPDATED: 21 May 2009 (20090521/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:


<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D STAT QUE L13

L2 STR



Structure attributes must be viewed using STN Express query preparation.

L4 150 SEA FILE=REGISTRY SSS FUL L2

L7 15 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L4

L8 2 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON ABRAHMSEN S?/AU
 L9 36 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON INGHARDT T?/AU
 L10 136 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON MAGNUSSON A?/AU
 L11 9 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON SIGFRIDSSON C?/AU
 L12 3 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON THUNE M?/AU
 L13 4 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON (L8 OR L9 OR L10 OR
 L11 OR L12) AND L7

=> FILE WPIX

FILE 'WPIX' ENTERED AT 14:57:27 ON 22 MAY 2009

COPYRIGHT (C) 2009 THOMSON REUTERS

FILE LAST UPDATED: 17 MAY 2009 <20090517/UP>

MOST RECENT UPDATE: 200931 <200931/DW>

DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> Now containing more than 1.3 million chemical structures in DCR <<<

>>> IPC, ECLA and US National Classifications have been updated with reclassifications to March 15th, 2009.

F-Term and FI-Term original classifications are current and reclassification will commence in June.

No update date (UP) has been created for the reclassified documents, but they can be identified by specific update codes (see HELP CLA for details)<<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:

http://www.stn-international.com/stn_guide.html

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

<http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/>

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:


http://www.stn-international.com/DWPIAnaVist2_0608.html

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

'BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> D STAT QUE L17

L2 STR



Structure attributes must be viewed using STN Express query preparation.

L8 2 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON ABRAHMSEN S?/AU

Serial No.:10/516,423

L9 36 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON INGHARDT T?/AU
 L10 136 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON MAGNUSSON A?/AU
 L11 9 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON SIGFRIDSSON C?/AU
 L12 3 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON THUNE M?/AU
 L15 80 SEA FILE=WPIX SSS FUL L2
 L16 11 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L15/DCR
 L17 5 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (L8 OR L9 OR L10 OR L11
 OR L12) AND L16

=> DUP REM L13 L17

FILE 'HCAPLUS' ENTERED AT 14:57:39 ON 22 MAY 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 14:57:39 ON 22 MAY 2009

COPYRIGHT (C) 2009 THOMSON REUTERS

PROCESSING COMPLETED FOR L13

PROCESSING COMPLETED FOR L17

L20 5 DUP REM L13 L17 (4 DUPLICATES REMOVED)

ANSWERS '1-4' FROM FILE HCAPLUS

ANSWER '5' FROM FILE WPIX

=> D IBIB ED ABS HITSTR 1-4; D IBIB AB HITSTR 5

L20 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2003:972051 HCAPLUS Full-text

DOCUMENT NUMBER: 140:27752

TITLE: [Chloro(difluoromethoxy)phenyl]hydroxyacetylazetidinecarboxamide derivative salts preparation as prodrugs
 INVENTOR(S): Ahlqvist, Matti; Bohlin, Martin; Inghardt, Tord; Lundblad, Anita; Sigfridsson, Carl-Gustaf

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 108 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101957	A1	20031211	WO 2003-SE859	20030527
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2487509	A1	20031211	CA 2003-2487509	20030527
AU 2003232871	A1	20031219	AU 2003-232871	20030527
BR 2003011365	A	20050301	BR 2003-11365	20030527
EP 1513806	A1	20050316	EP 2003-728206	20030527
EP 1513806	B1	20090318		

Serial No.:10/516,423

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1656067	A	20050817	CN 2003-812491	20030527
JP 2005532346	T	20051027	JP 2004-509651	20030527
NZ 536738	A	20070531	NZ 2003-536738	20030527
NZ 554323	A	20081031	NZ 2003-554323	20030527
RU 2345064	C2	20090127	RU 2004-133388	20030527
AT 425963	T	20090415	AT 2003-728206	20030527
EP 2055696	A1	20090506	EP 2009-151657	20030527

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR, AL, LT, LV, MK

IN 2004DN03465	A	20050401	IN 2004-DN3465	20041108
ZA 2004009228	A	20050517	ZA 2004-9228	20041117
MX 2004011912	A	20050331	MX 2004-11912	20041129
US 20050234035	A1	20051020	US 2005-516422	20050520
US 7273858	B2	20070925		
IN 2007DN00996	A	20070803	IN 2007-DN996	20070206
US 20080269176	A1	20081030	US 2007-839842	20070816


PRIORITY APPLN. INFO.:

SE 2002-1661	A	20020531
EP 2003-728206	A3	20030527
NZ 2003-536738	A3	20030527
WO 2003-SE859	W	20030527
IN 2004-DN3465	A3	20041108
US 2005-516422	A1	20050520

OTHER SOURCE(S): MARPAT 140:27752

ED Entered STN: 14 Dec 2003

GI



I

AB There is provided pharmaceutically-acceptable acid addition salts of compds. of such as I. I was prepared along with two other similar compds. Salts of I prepared include the ethanesulfonate and benzenesulfonate. The salts are useful as prodrugs of competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

IT 433937-93-0P 433938-09-1P 433938-32-0P
433938-43-3P 433939-99-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

([chloro(difluoromethoxy)phenyl]hydroxyacetylazetidinecarboxamide derivative salts preparation as prodrugs)

RN 433937-93-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[4-[imino(methoxyamino)methyl]phenyl]methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-09-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 433938-32-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 433938-43-3 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-(azetidinyl)carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—Cl

RN 433939-99-2 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonylamino]methyl]-3,5-difluorophenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



-C1


IT 631916-71-7P 631916-73-9P 631916-75-1P
 631916-76-2P 631916-77-3P 631916-79-5P
 631916-81-9P 631916-83-1P 631916-91-1P
 631916-97-7P 631917-18-5P 631917-19-6P
 631917-20-9P 631917-21-0P 631917-22-1P
 631917-23-2P 631917-24-3P 631917-25-4P
 631917-27-6P 631917-28-7P 631917-29-8P
 631917-30-1P 631917-45-8P 633315-91-0P
 633315-92-1P 633315-93-2P 633315-95-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 ([chloro(difluoromethoxy)phenyl]hydroxyacetylazetidinecarboxamide
 derivative salts preparation as prodrugs)
 RN 631916-71-7 HCAPLUS
 CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-,
 (1S,4R)-, compd. with (2S)-1-[(2R)-[3-chloro-5-
 (difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (9CI) (CA INDEX NAME)
 CM 1
 CRN 433937-93-0
 CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2
 CRN 3144-16-9
 CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).



RN 631916-73-9 HCAPLUS


CN Sulfamic acid, cyclohexyl-, compd. with
(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 100-88-9

CMF C6 H13 N O3 S



RN 631916-75-1 HCAPLUS


CN Phosphoric acid, dimethyl ester, compd. with
(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 813-78-5

CMF C2 H7 O4 P



RN 631916-76-2 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



RN 631916-77-3 HCAPLUS


CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631916-79-5 HCAPLUS


CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1),
monohydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631916-81-9 HCAPLUS


CN 2-Azetidinedicarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 631916-83-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrochloride (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 631916-91-1 HCAPLUS


CN Ethanesulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 594-45-6

CMF C2 H6 O3 S



RN 631916-97-7 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, benzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



RN 631917-18-5 HCAPLUS


CN 1-Propanesulfonic acid, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 5284-66-2

CMF C3 H8 O3 S




RN 631917-19-6 HCAPLUS

CN 1-Butanesulfonic acid, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (CA INDEX NAME)

CM 1


CRN 433937-93-0
 CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 2386-47-2
 CMF C4 H10 O3 S




RN 631917-20-9 HCAPLUS
 CN Ethanesulfonic acid, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0
 CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 594-45-6

CMF C2 H6 O3 S



RN 631917-21-0 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-(imino(methoxyamino)methyl)phenyl)methyl]-, (2S)-, benzenesulfonate (1:1)
(CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



RN 631917-22-1 HCAPLUS

CN Sulfamic acid, cyclohexyl-, compd. with

Serial No.:10/516,423


(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 100-88-9

CMF C6 H13 N O3 S



RN 631917-23-2 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-93-9


CMF H2 O4 S



RN 631917-24-3 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrobromide (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



● HBr

RN 631917-25-4 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



RN 631917-27-6 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, sulfate (2:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 631917-28-7 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl)methyl]-, (2S)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 631917-29-8 HCAPLUS

Serial No.:10/516,423


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7697-37-2


CMF H N O3



RN 631917-30-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrochloride (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 631917-45-8 HCAPLUS


CN 1,5-Naphthalenedisulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-
difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-
azetidinecarboxamide (1:2) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 81-04-9

CMF C10 H8 O6 S2




RN 633315-91-0 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, (2Z)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0
 CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.




RN 633315-92-1 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, phosphate (3:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0
 CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-38-2

CMF H3 O4 P



RN 633315-93-2 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[4-[imino(methoxyamino)methyl]phenylmethyl]-, (2S)-, compd. with 1,2-benzisothiazol-3(2H)-one 1,1-dioxide, sodium salt (1:1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 128-44-9

CMF C7 H5 N O3 S . Na



● Na

RN 633315-95-4 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, mononaphthalenesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 25155-19-5

CMF C10 H8 O3 S

CCI IDS

D1-SO₃H


Serial No.:10/516,423

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 2
 ACCESSION NUMBER: 2003:971865 HCAPLUS Full-text
 DOCUMENT NUMBER: 140:31486
 TITLE: Modified-release pharmaceutical formulation containing cardiovascular agents
 INVENTOR(S): Magnussón, Anders; Thune, Mikael
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
 SOURCE: PCT Int. Appl., 115 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101424	A1	20031211	WO 2003-SE858	20030527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2485535	A1	20031211	CA 2003-2485535	20030527
AU 2003232870	A1	20031219	AU 2003-232870	20030527
EP 1513495	A1	20050316	EP 2003-728205	20030527
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011460	A	20050329	BR 2003-11460	20030527
CN 1655761	A	20050817	CN 2003-812492	20030527
CN 100402025	C	20080716		
JP 2005536472	T	20051202	JP 2004-508782	20030527
NZ 536621	A	20061027	NZ 2003-536621	20030527
NZ 549176	A	20071221	NZ 2003-549176	20030527
CN 101264051	A	20080917	CN 2008-10099130	20030527
RU 2352323	C2	20090420	RU 2004-132856	20030527
NO 2004004767	A	20050225	NO 2004-4767	20041103
IN 2004DN03415	A	20090227	IN 2004-DN3415	20041103
ZA 2004009234	A	20050712	ZA 2004-9234	20041117
MX 2004011914	A	20050331	MX 2004-11914	20041129
US 20050171083	A1	20050804	US 2004-516420	20041129
US 7202236	B2	20070410		
IN 2006DN06241	A	20070831	IN 2006-DN6241	20061025
US 20080050437	A1	20080228	US 2007-716021	20070309
PRIORITY APPLN. INFO.:			SE 2002-1659	A 20020531
			CN 2003-812492	A3 20030527
			NZ 2003-536621	A3 20030527
			WO 2003-SE858	W 20030527
			IN 2004-DN3415	A3 20041103
			US 2004-516420	A1 20041129

OTHER SOURCE(S): MARPAT 140:31486
 ED Entered STN: 14 Dec 2003
 GI



I

AB Disclosed is a modified-release pharmaceutical composition comprising, as active ingredient, a compound of formula I (R1 = Cl-2 alkyl substituted by one or more fluoro substituents; R2 = H, OH, OMe, OEt; and n = 0-2) or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier. The formulation may only contain ι-carrageenan and a neutral gelling polymer when the compound of formula I is in the form of a salt; such formulations being of use for the treatment of a cardiovascular disorder. A compound Ph(3-Cl)(5-OCHF2)-(R)-CH(OH)C(O)-(S)-Aze-Pab(OMe) esylate salt was prepared, its 50.5 mg was combined with hydroxypropyl Me cellulose 200, and sodium stearyl fumarate 2.5 mg to obtain a modified-release tablets.


IT 631916-71-7P 631916-72-8P 631916-73-9P
 631916-74-0P 631916-75-1P 631916-76-2P
 631916-77-3P 631916-79-5P 631916-80-8P
 631916-81-9P 631916-83-1P 631916-85-3P
 631916-86-4P 631916-87-5P 631916-89-7P
 631916-91-1P 631916-92-2P 631916-93-3P
 631916-94-4P 631916-95-5P 631916-96-6P
 631916-97-7P 631916-98-8P 631917-01-6P
 631917-03-8P 631917-04-9P 631917-05-0P
 631917-06-1P 631917-07-2P 631917-09-4P
 631917-11-8P 631917-13-0P 631917-15-2P
 631917-17-4P 631917-20-9P 631917-21-0P
 631917-22-1P 631917-23-2P 631917-24-3P
 631917-25-4P 631917-26-5P 631917-27-6P
 631917-28-7P 631917-29-8P 631917-30-1P
 631917-31-2P 631917-32-3P 631917-33-4P
 631917-34-5P 631917-35-6P 631917-36-7P
 631917-37-8P 631917-39-0P 631917-40-3P
 631917-42-5P 631917-43-6P 631917-44-7P
 631917-45-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (modified-release pharmaceutical formulation containing cardiovascular agents)

RN 631916-71-7 HCAPLUS

CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-(imino(methoxyamino)methyl]phenyl]methyl]-2-azetidincarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 631916-73-9 HCAPLUS


CN Sulfamic acid, cyclohexyl-, compd. with
(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 100-88-9

CMF C6 H13 N O3 S



RN 631916-74-0 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, phosphate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 631916-75-1 HCAPLUS

CN Phosphoric acid, dimethyl ester, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 813-78-5
CMF C2 H7 O4 P




RN 631916-76-2 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



RN 631916-77-3 HCAPLUS


CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631916-79-5 HCAPLUS

CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1),

Serial No.:10/516,423


monohydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631916-80-8 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, compd. with 1,2-benzisothiazol-3(2H)-one 1,1-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 81-07-2

CMF C7 H5 N O3 S



RN 631916-81-9 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 631916-83-1 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrochloride (1:1), (2S)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 631916-85-3 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrobromide (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



● HBr


RN 631916-86-4 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, sulfate (2:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 631916-87-5 HCAPLUS
 CN 1,2-Ethanedithiolonic acid, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 110-04-3

CMF C2 H6 O6 S2



RN 631916-89-7 HCAPLUS


CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 5872-08-2

CMF C10 H16 O4 S




RN 631916-91-1 HCAPLUS
 CN Ethanesulfonic acid, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 594-45-6

CMF C2 H6 O3 S




RN 631916-92-2 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-
 hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-,
 nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 7697-37-2

CMF H N O3



RN 631916-93-3 HCAPLUS


CN Benzenesulfonic acid, 2,5-dimethyl-, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 609-54-1

CMF C8 H10 O3 S



RN 631916-94-4 HCAPLUS


CN Benzenesulfonic acid, 2,4,6-trimethyl-, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 3453-83-6

CMF C9 H12 O3 S




RN 631916-95-5 HCAPLUS

CN 1,5-Naphthalenedisulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:2)
(CA INDEX NAME)

CM 1

CRN 433937-93-0
 CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 81-04-9
 CMF C10 H8 O6 S2




RN 631916-96-6 HCAPLUS
 CN Naphthalenesulfonic acid, compd. with
 (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0
 CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 25155-19-5
CMF C10 H8 O3 S
CCI IDS




D1-SO₃H

RN 631916-97-7 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, benzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 98-11-3
CMF C6 H6 O3 S




RN 631916-98-8 HCAPLUS
 CN D-Glutamic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0
 CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 6893-26-1
 CMF C5 H9 N O4

Absolute stereochemistry.




RN 631917-01-6 HCAPLUS
 CN L-Glutamic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0
 CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-86-0

CMF C5 H9 N O4

Absolute stereochemistry.



RN 631917-03-8 HCAPLUS


CN Glutamic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 617-65-2

CMF C5 H9 N O4



RN 631917-04-9 HCAPLUS


CN L-Arginine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 631917-05-0 HCAPLUS

CN Glycine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1


CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 56-40-6
CMF C2 H5 N O2




RN 631917-06-1 HCAPLUS
CN Benzoic acid, 2-hydroxy-, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 69-72-7
CMF C7 H6 O3




RN 631917-07-2 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 631917-09-4 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 631917-11-8 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 77-92-9

CMF C6 H8 O7



RN 631917-13-0 HCAPLUS


CN Butanedioic acid, 2-hydroxy-, (2S)-(2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 97-67-6

CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



RN 631917-15-2 HCAPLUS

CN Butanedioic acid, 2-hydroxy-, (2S)-compd. with

Serial No.:10/516,423


1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 6915-15-7

CMF C4 H6 O5



RN 631917-17-4 HCAPLUS


CN D-Gluconic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 526-95-4

CMF C6 H12 O7

Absolute stereochemistry.



RN 631917-20-9 HCAPLUS


CN Ethanesulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-
difluoro-4-[(imino(methoxyamino)methyl]phenyl)methyl]-2-
azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0


CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 594-45-6
CMF C2 H6 O3 S




RN 631917-21-0 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, benzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 98-11-3
CMF C6 H6 O3 S




RN 631917-22-1 HCAPLUS
CN Sulfamic acid, cyclohexyl-, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 100-88-9

CMF C6 H13 N O3 S



RN 631917-23-2 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-93-9


CMF H2 O4 S



RN 631917-24-3 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl)methyl]-, hydrobromide (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



● HBr

RN 631917-25-4 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl)methyl]-, (2S)-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



RN 631917-26-5 HCAPLUS


CN 2-Naphthalenesulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 120-18-3

CMF C10 H8 O3 S




RN 631917-27-6 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, sulfate (2:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 631917-28-7 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 631917-29-8 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7697-37-2


CMF H N O3



RN 631917-30-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrochloride (1:1), (2S)-(CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 631917-31-2 HCAPLUS


CN 1,2-Ethanedisulfonic acid, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:2) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 110-04-3

CMF C2 H6 O6 S2



RN 631917-32-3 HCAPLUS


CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 3144-16-9

CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).




RN 631917-33-4 HCAPLUS
 CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 5872-08-2

CMF C10 H16 O4 S




RN 631917-34-5 HCAPLUS
 CN Benzenesulfonic acid, 2,5-dimethyl-, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 609-54-1

CMF C8 H10 O3 S



RN 631917-35-6 HCAPLUS


CN Benzenesulfonic acid, 2,4,6-trimethyl-, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-
 difluoro-4-(imino(methoxyamino)methyl]phenyl]methyl]-2-
 azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 3453-83-6

CMF C9 H12 O3 S



RN 631917-36-7 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, compd. with 1,2-benzisothiazol-3(2H)-one 1,1-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 81-07-2

CMF C7 H5 N O3 S




RN 631917-37-8 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 631917-39-0 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, phosphate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-38-2

CMF H3 O4 P



RN 631917-40-3 HCAPLUS


CN D-Glutamic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[(2,6-difluoro-4-[(imino(methoxyamino)methyl)phenyl)methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 6893-26-1

CMF C5 H9 N O4

Absolute stereochemistry.



RN 631917-42-5 HCAPLUS


CN L-Arginine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 631917-43-6 HCAPLUS


CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631917-44-7 HCAPLUS


CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1), monohydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631917-45-8 HCAPLUS


CN 1,5-Naphthalenedisulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-
difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-
azetidinecarboxamide (1:2) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2


CRN 81-04-9

CMF C10 H8 O6 S2




IT 433937-93-0 433938-09-1 433938-32-0
 631917-18-5 631917-19-6 631917-46-9
 631917-47-0 631917-48-1
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (modified-release pharmaceutical formulation containing cardiovascular
 agents)
 RN 433937-93-0 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-
 hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-09-1 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-
 hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-
 (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-32-0 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-
 hydroxyacetyl]-N-[[2,6-difluoro-4-
 [imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 631917-18-5 HCAPLUS


CN 1-Propanesulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 5284-66-2

CMF C3 H8 O3 S



RN 631917-19-6 HCAPLUS

CN 1-Butanesulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)


(CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 2386-47-2

CMF C4 H10 O3 S



RN 631917-46-9 HCAPLUS


CN 1-Propanesulfonic acid, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[(2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl)methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 5284-66-2

CMF C3 H8 O3 S



RN 631917-47-0 HCAPLUS


CN 1-Butanesulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[(2,6-difluoro-4-{imino(methoxyamino)methyl}phenyl)methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 2386-47-2

CMF C4 H10 O3 S



RN 631917-48-1 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, benzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-09-1

CMF C23 H26 Cl F N4 O5

Absolute stereochemistry.



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 3


ACCESSION NUMBER: 2003:971864 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:31485

TITLE: Immediate-release pharmaceutical formulation of amidine compounds

INVENTOR(S): Abrahamsen Alami, Susanna; Inghardt, Tord;
 Magnusson, Anders; Sigfridsson,
 Carl-Gustaf; Thune, Mikael
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 127 pp.
 CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

OTHER SOURCE(S): MARPAT 140:31485
ED Entered STN: 14 Dec 2003
GI



AB An immediate-release pharmaceutical formulation is provided comprising (a) as active ingredient, a compound of formula I (R1 = C1-2 alkyl substituted by one or more fluoro substituents; R2 = H, OH, OMe, OEt; n = 0, 1, 2) or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable diluent or carrier. When the active ingredient is other than in the form of a salt, the formulation does not solely contain (i) a solution of one active ingredient and water, (ii) a solution of one active ingredient and DMSO, or (iii) a solution of one active ingredient in a mixture of ethanol/PEG 660 12-hydroxy stearate/water (5:5:90). Such formulations are used for the treatment of a cardiovascular disorder. For example, a solution was prepared by dissolving Compound A [I (R1 = CHF2, R2 = OMe, n = 0) (preparation given)] in a hydroxypropyl- β -cyclodextrin/water diluent (40:60 weight/weight%) (136 μ mol Compound A to 1 mL diluent) and adjusting pH to 3.7 with HCl. The solubility of Compound A was at least 700 times higher in this vehicle compared to water alone.

IT 433937-73-6P 433937-74-7P 433937-93-0DP, salts
with saccharinic acid 433937-93-0P 433938-07-9P

433938-09-1P 433938-21-7P 433938-22-8P

433938-31-9P 433938-32-0P 631916-71-7P

631916-72-8P 631916-73-9P 631916-74-0P

631916-75-1P 631916-76-2P 631916-77-3P

631916-79-5P 631916-80-8P 631916-81-9P

631916-83-1P 631916-85-3P 631916-86-4P

631916-89-7P 631916-91-1P 631916-92-2P

631916-93-3P 631916-94-4P 631916-95-5P

631916-97-7P 631916-98-8P 631917-01-6P

631917-03-8P 631917-04-9P 631917-05-0P

631917-06-1P 631917-07-2P 631917-09-4P

631917-11-8P 631917-13-0P 631917-15-2P

631917-17-4P 631917-18-5P 631917-19-6P

631917-20-9P 631917-21-0P 631917-22-1P

631917-23-2P 631917-24-3P 631917-25-4P

631917-26-5P 631917-27-6P 631917-28-7P

631917-29-8P 631917-30-1P 631917-31-2P

631917-32-3P 631917-33-4P 631917-34-5P

631917-35-6P 631917-36-7P 631917-37-8P

631917-39-0P 631917-40-3P 631917-42-5P

631917-43-6P 631917-44-7P 631917-45-8P

634151-54-5P 634151-59-0P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);


BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and immediate-release formulation of amidine compds. for treatment of thrombosis)

RN 433937-73-6 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-, (2S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 433937-74-7 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-93-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-93-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-07-9 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-09-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-21-7 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2,2-difluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-, (2S)-

(CA INDEX NAME)


Absolute stereochemistry.



RN 433938-22-8 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-31-9 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)-2,6-difluorophenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-32-0 HCAPLUS

Serial No.:10/516,423

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 631916-71-7 HCAPLUS


CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 3144-16-9

CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).




RN 631916-72-8 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0
 CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.




RN 631916-73-9 HCAPLUS
 CN Sulfamic acid, cyclohexyl-, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 100-88-9
CMF C6 H13 N O3 S




RN 631916-74-0 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-(methoxyamino)methyl]phenyl]methyl]-, (2S)-, phosphate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-38-2

CMF H3 O4 P



RN 631916-75-1 HCAPLUS


CN Phosphoric acid, dimethyl ester, compd. with
 (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 813-78-5

CMF C2 H7 O4 P



RN 631916-76-2 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-
 hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-,

Serial No.:10/516,423


4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



RN 631916-77-3 HCAPLUS


CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631916-79-5 HCAPLUS


CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1), monohydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631916-80-8 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, compd. with 1,2-benzisothiazol-3(2H)-one 1,1-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 81-07-2

CMF C7 H5 N O3 S



RN 631916-81-9 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 631916-83-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[4-[imino(methoxyamino)methyl]phenylmethyl]-, hydrochloride (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 631916-85-3 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrobromide (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 631916-86-4 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, sulfate (2:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 631916-89-7 HCAPLUS
 CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 5872-08-2

CMF C10 H16 O4 S




RN 631916-91-1 HCAPLUS
 CN Ethanesulfonic acid, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 594-45-6

CMF C2 H6 O3 S



RN 631916-92-2 HCAPLUS


CN 2-Azetidinedicarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 7697-37-2

CMF H N O3



RN 631916-93-3 HCAPLUS


CN Benzenesulfonic acid, 2,5-dimethyl-, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 609-54-1

CMF C8 H10 O3 S




RN 631916-94-4 HCAPLUS

CN Benzenesulfonic acid, 2,4,6-trimethyl-, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (CA INDEX NAME)


CM 1

CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2
CRN 3453-83-6
CMF C9 H12 O3 S



RN 631916-95-5 HCAPLUS
CN 1,5-Naphthalenedisulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinedicarboxamide (1:2)
(CA INDEX NAME)

CM 1
CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 81-04-9

CMF C10 H8 O6 S2



RN 631916-97-7 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, benzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



RN 631916-98-8 HCAPLUS

Serial No.:10/516,423


CN D-Glutamic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 6893-26-1

CMF C5 H9 N O4

Absolute stereochemistry.



RN 631917-01-6 HCAPLUS

CN L-Glutamic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)


CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.

CMF C5 H9 N O4



RN 631917-04-9 HCAPLUS


CN L-Arginine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 631917-05-0 HCAPLUS

CN Glycine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1


CRN 433937-93-0
 CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 56-40-6
 CMF C2 H5 N O2




RN 631917-06-1 HCAPLUS
 CN Benzoic acid, 2-hydroxy-, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (CA INDEX NAME)

CM 1

CRN 433937-93-0
 CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 69-72-7
CMF C7 H6 O3




RN 631917-07-2 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 631917-09-4 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 631917-11-8 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 77-92-9

CMF C6 H8 O7



RN 631917-13-0 HCAPLUS


CN Butanedioic acid, 2-hydroxy-, (2S)-(2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 97-67-6

CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



RN 631917-15-2 HCAPLUS

CN Butanedioic acid, 2-hydroxy-, (2S)-compd. with

Serial No.:10/516,423


1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 6915-15-7

CMF C4 H6 O5



RN 631917-17-4 HCAPLUS


CN D-Gluconic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 526-95-4

CMF C6 H12 O7

Absolute stereochemistry.



RN 631917-18-5 HCAPLUS


CN 1-Propanesulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 433937-93-0


CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 5284-66-2
CMF C3 H8 O3 S




RN 631917-19-6 HCAPLUS
CN 1-Butanesulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1


CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 2386-47-2
CMF C4 H10 O3 S




RN 631917-20-9 HCAPLUS
CN Ethanesulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-
difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-
azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 594-45-6

CMF C2 H6 O3 S



RN 631917-21-0 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[(imino(methoxyamino)methyl)phenyl)methyl]-, (2S)-, benzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2
CRN 98-11-3
CMF C6 H6 O3 S




RN 631917-22-1 HCAPLUS
CN Sulfamic acid, cyclohexyl-, compd. with
(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1
CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2
CRN 100-88-9
CMF C6 H13 N O3 S



RN 631917-23-2 HCAPLUS

Serial No.:10/516,423


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-93-9


CMF H2 O4 S



RN 631917-24-3 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrobromide (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



● HBr


RN 631917-25-4 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



RN 631917-26-5 HCAPLUS
 CN 2-Naphthalenesulfonic acid, (2S)-compd. with

Serial No.:10/516,423


1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 120-18-3

CMF C10 H8 O3 S



RN 631917-27-6 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, sulfate (2:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 631917-28-7 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 631917-29-8 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2


CRN 7697-37-2

CMF H N O3



RN 631917-30-1 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrochloride (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 631917-31-2 HCAPLUS


CN 1,2-Ethanedisulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-
difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-
azetidinecarboxamide (1:2) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 110-04-3

CMF C2 H6 O6 S2



RN 631917-32-3 HCAPLUS

CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-,
(1S,4R)-, compd. with (2S)-1-[(2R)-[3-chloro-5-
(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-

Serial No.:10/516,423


[imino(methoxyamino)methyl]phenyl)methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 3144-16-9

CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).



RN 631917-33-4 HCAPLUS


CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-,
(2S)-compd. with 1-[(2R)-2-[[2,6-difluoro-4-[[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 5872-08-2

CMF C10 H16 O4 S



RN 631917-34-5 HCAPLUS


CN Benzenesulfonic acid, 2,5-dimethyl-, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-
difluoro-4-[(imino(methoxyamino)methyl]phenyl)methyl]-2-
azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 609-54-1

CMF C8 H10 O3 S



RN 631917-35-6 HCAPLUS


CN Benzenesulfonic acid, 2,4,6-trimethyl-, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-
 difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-
 azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 3453-83-6

CMF C9 H12 O3 S




RN 631917-36-7 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-
 hydroxyacetyl]-N-[[2,6-difluoro-4-
 [imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, compd. with
 1,2-benzisothiazol-3(2H)-one 1,1-dioxide (1:1) (CA INDEX NAME)

CM 1


CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 81-07-2
CMF C7 H5 N O3 S




RN 631917-37-8 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxycarbonyl)methyl]phenyl]methyl]-, (2S)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 631917-39-0 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, phosphate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 631917-40-3 HCAPLUS
 CN D-Glutamic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 6893-26-1

CMF C5 H9 N O4

Absolute stereochemistry.




RN 631917-42-5 HCAPLUS
 CN L-Arginine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2
CRN 74-79-3
CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 631917-43-6 HCAPLUS
CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1
CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631917-44-7 HCAPLUS


CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1), monohydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 631917-45-8 HCAPLUS
 CN 1,5-Naphthalenedisulfonic acid, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-
 difluoro-4-[(imino(methoxyamino)methyl]phenyl)methyl]-2-
 azetidinecarboxamide (1:2) (CA INDEX NAME)

CM 1

CRN 433938-32-0
 CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 81-04-9
 CMF C10 H8 O6 S2



RN 634151-54-5 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-
 hydroxyacetyl]-N-[[2,6-difluoro-4-
 [(hydroxyamino)iminomethyl]phenyl)methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 634151-59-0 HCAPLUS


CN 1,2-Ethanedisulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:2)
(CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 110-04-3

CMF C2 H6 O6 S2



IT 433938-43-3P 433939-57-2P 433939-99-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and immediate-release formulation of amidine compds. for
treatment of thrombosis)

RN 433938-43-3 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-
(difluoromethoxy)phenyl]hydroxyacetyl]-2-

azetidiny]carbonyl]amino)methyl]phenyl]iminomethyl]-,
2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A

Me₃Si

F₂CH

O


R

OH

S


- C1

Absolute stereochemistry.



Page 120 of 381

Absolute stereochemistry.



PAGE 1-B

—C1

IT 433937-75-8P 433938-08-0P 634151-60-3P
634151-61-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and immediate-release formulation of amidine compds. for treatment of thrombosis)

RN 433937-75-8 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-74-7

CMF C21 H21 Cl F2 N4 O4

Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 433938-08-0 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1
 CRN 433938-07-9
 CMF C22 H24 Cl F N4 O4

Absolute stereochemistry.



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 634151-60-3 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)-2,6-difluorophenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-


hydroxyacetyl]-, acetate (1:1), (2S)- (CA INDEX NAME)

CM 1

CRN 433938-31-9

CMF C21 H19 Cl F4 N4 O4

Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2



RN 634151-61-4 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, acetate (1:1), (2S)- (CA INDEX NAME)

CM 1

CRN 433937-74-7

CMF C21 H21 Cl F2 N4 O4

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 4
 ACCESSION NUMBER: 2002:428874 HCAPLUS Full-text
 DOCUMENT NUMBER: 137:20289
 TITLE: New mandelic acid derivatives and their use as thrombin inhibitors
 INVENTOR(S): Inghardt, Tord; Johansson, Anders; Svensson, Arne
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
 SOURCE: PCT Int. Appl., 204 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002044145	A1	20020606	WO 2001-SE2657	20011130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2436220	A1	20020606	CA 2001-2436220	20011130
AU 2002018618	A	20020611	AU 2002-18618	20011130
EE 200300259	A	20030815	EE 2003-259	20011130
BR 2001015861	A	20030923	BR 2001-15861	20011130
EP 1347955	A1	20031001	EP 2001-998535	20011130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002487	A2	20031128	HU 2003-2487	20011130
JP 2004520290	T	20040708	JP 2002-546515	20011130
JP 4177101	B2	20081105		
NZ 526205	A	20050429	NZ 2001-526205	20011130
CN 1291975	C	20061227	CN 2001-822316	20011130
CN 1939902	A	20070404	CN 2006-10143376	20011130
CN 1939903	A	20070404	CN 2006-10143381	20011130
RU 2300521	C2	20070610	RU 2003-115420	20011130
CA 2456426	A1	20030306	CA 2002-2456426	20020830


Serial No.:10/516,423

WO 2003018551	A1	20030306	WO 2002-SE1557	20020830
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002324410	A1	20030310	AU 2002-324410	20020830
AU 2002324410	B2	20080424		
EP 1423362	A1	20040602	EP 2002-759050	20020830
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011847	A	20040908	BR 2002-11847	20020830
CN 1549808	A	20041124	CN 2002-816924	20020830
CN 1301969	C	20070228		
HU 2004001189	A2	20041228	HU 2004-1189	20020830
JP 2005504057	T	20050210	JP 2003-523215	20020830
NZ 531109	A	20060331	NZ 2002-531109	20020830
RU 2341516	C2	20081220	RU 2004-103625	20020830
TW 264434	B	20061021	TW 2002-91132920	20211108
ZA 2003003830	A	20040816	ZA 2003-3830	20030516
BG 107825	A	20040227	BG 2003-107825	20030519
IN 2003DN00780	A	20090227	IN 2003-DN780	20030520
US 20040019033	A1	20040129	US 2003-432411	20030521
US 7129233	B2	20061031		
MX 2003004794	A	20030910	MX 2003-4794	20030529
NO 325228	B1	20080303	NO 2003-2465	20030530
ZA 2004001083	A	20050510	ZA 2004-1083	20040210
IN 2004MN00099	A	20060203	IN 2004-MN99	20040210
NO 326496	B1	20081215	NO 2004-813	20040224
MX 2004001825	A	20040708	MX 2004-1825	20040226
US 20040242492	A1	20041202	US 2004-487805	20040226
US 7056907	B2	20060606		
US 20070202174	A1	20070830	US 2006-520063	20060913
US 20070218136	A1	20070920	US 2006-520052	20060913
IN 2006DN07847	A	20070824	IN 2006-DN7847	20061222
IN 2006DN07848	A	20070824	IN 2006-DN7848	20061222
US 20080090800	A1	20080417	US 2007-797656	20070504
AU 2007203509	A1	20070816	AU 2007-203509	20070727
AU 2007203520	A1	20070816	AU 2007-203520	20070727
JP 2008138009	A	20080619	JP 2008-6611	20080116
JP 2008156362	A	20080710	JP 2008-6608	20080116
KR 2008059681	A	20080630	KR 2008-714404	20080613
KR 2008064204	A	20080708	KR 2008-714402	20080613
KR 2009023745	A	20090305	KR 2009-702806	20090211
PRIORITY APPLN. INFO.:			SE 2000-4458	A 20001201
			SE 2001-965	A 20010319
			SE 2001-1239	A 20010406
			SE 2001-2921	A 20010830
			TW 2001-90129207	A 20011126
			CN 2001-822316	A3 20011130
			JP 2002-546515	A3 20011130
			WO 2001-SE2657	W 20011130
			WO 2002-SE1557	W 20020830
			IN 2003-DN780	A3 20030520
			US 2003-432411	A3 20030521

KR 2003-707353
US 2006-520063
KR 2008-714402

A3 20030531
A1 20060913
A3 20080613

OTHER SOURCE(S): MARPAT 137:20289
ED Entered SIN: 07 Jun 2002
GI



II

AB Mandelic acid derivs. I [R = substituted Ph; R1 = OH, CH2OH; X = C6H4, (di)azaphenylene; Y = CH2, CH2CH2] and pharmaceutically-acceptable prodrugs thereof, were prep'd for use as competitive inhibitors of trypsin-like proteases, such as thrombin, or as anticoagulants. Thus, 3,5-Cl(F2CHO)C6H3CHO was prepared from 3,5-Cl2C6H3OMe and was converted to 3,5-Cl(F2CHO)C6H3CH(OSiMe3)CN which was hydrolyzed and resolved with lipase to give (R)-3,5-Cl(F2CHO)C6H3CH(OH)CO2H. This acid was used to acylate the azetidine fragment and deblocked to give the amide (R)-II which had an IC50 <0.02 µM in the thrombin clotting time test.

IT 433937-72-5P 433937-73-6P 433937-74-7P
433937-75-8P 433937-76-9P 433937-77-0P
433937-78-1P 433937-79-2P 433937-80-5P
433937-81-6P 433937-93-0P 433937-98-5P
433937-99-6P 433938-00-2P 433938-01-3P
433938-02-4P 433938-03-5P 433938-04-6P
433938-05-7P 433938-06-8P 433938-07-9P
433938-08-0P 433938-09-1P 433938-10-4P
433938-11-5P 433938-12-6P 433938-13-7P
433938-14-8P 433938-15-9P 433938-16-0P
433938-17-1P 433938-18-2P 433938-19-3P
433938-20-6P 433938-21-7P 433938-30-8P
433938-31-9P 433938-32-0P 433938-33-1P
433938-35-3P 433938-36-4P 433938-37-5P
433938-51-3P 433938-52-4P 433938-53-5P
433938-54-6P 433938-55-7P 433938-56-8P
433938-57-9P 433938-58-0P 433938-59-1P
433938-60-4P 433938-61-5P 433938-62-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of mandeloylazetidinedicarboxamides as thrombin inhibitors)

RN 433937-72-5 HCAPLUS

CN 2-Azetidinedicarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(cyclobutylamino)iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-73-6 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[4-[(hydroxyamino)iminomethyl]phenyl]methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-74-7 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433937-75-8 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-74-7

CMF C21 H21 Cl F2 N4 O4

Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 433937-76-9 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-77-0 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-78-1 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433937-79-2 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-

Serial No.:10/516,423


[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-78-1

CMF C21 H20 Cl F3 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433937-80-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 433937-81-6 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino[(5-methyl-3-isoxazolyl)methoxy]amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-93-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-98-5 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2,2,2-trifluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433937-99-6 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2,2,2-trifluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-98-5
 CMF C22 H22 Cl F3 N4 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 433938-00-2 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2,2,2-trifluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-01-3 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2,2-difluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-02-4 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2,2-difluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-01-3

CMF C22 H23 Cl F2 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-03-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2,2-difluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-04-6 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(fluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-05-7 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(fluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-,


2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-04-6

CMF C21 H22 Cl F N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-06-8 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(fluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-07-9 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-08-0 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-07-9

CMF C22 H24 Cl F N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-09-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-10-4 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-11-5 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-10-4

CMF C23 H25 Cl F2 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-12-6 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoro-1-(fluoromethyl)ethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-(imino(methoxyamino)methyl)phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-13-7 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-(difluoromethoxy)-5-fluorophenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-14-8 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-(difluoromethoxy)-5-fluorophenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-13-7

CMF C21 H21 F3 N4 O4

Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 433938-15-9 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-(difluoromethoxy)-5-fluorophenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-16-0 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-bromo-5-(fluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-17-1 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-bromo-5-(fluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-16-0

CMF C21 H22 Br F N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-18-2 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-bromo-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-19-3 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-bromo-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-18-2

CMF C21 H21 Br F2 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-20-6 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-bromo-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(imino(methoxyamino)methyl]phenyl)methyl]-, (2S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 433938-21-7 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2,2-difluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(hydroxyamino)iminomethyl]phenyl)methyl]-, (2S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 433938-30-8 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)-3-fluorophenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-31-9 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)-2,6-difluorophenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-32-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-33-1 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)-2,5-difluorophenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-35-3 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-(ethoxyamino)iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-36-4 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(propoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

(CA INDEX NAME)


Absolute stereochemistry.



RN 433938-37-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(1-methylethoxy)amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-51-3 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(3-pyridinylmethoxy)amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-52-4 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(2-methylpropoxy)amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-53-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(ethoxyamino)iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-54-6 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(phenylmethoxy)amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-55-7 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[4-[(cyclohexyloxy)amino]iminomethyl]phenyl)methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-56-8 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[4-[(cyclobutyloxy)amino]iminomethyl]phenyl)methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-57-9 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[4-[imino[2-[3-(trifluoromethyl)phenoxy]ethoxy]amino]methyl]phenyl)methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-58-0 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-[[[(4-chlorophenyl)methoxy]amino]iminomethyl]phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-59-1 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino[(3-methoxyphenyl)methoxy]amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-60-4 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-[[[(2-bromophenyl)methoxy]amino]iminomethyl]phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-61-5 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[[imino[(4-methylphenyl)methoxy]amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-62-6 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[[imino[(1-propylbutoxy)amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 433938-43-3P 433938-50-2P 433938-88-6P
 433938-96-6P 433939-08-3P 433939-18-5P
 433939-26-5P 433939-38-9P 433939-47-0P
 433939-55-0P 433939-57-2P 433939-58-3P
 433939-99-2P 433940-15-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of mandeloylazetidinecarboxamides as thrombin inhibitors)

RN 433938-43-3 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B

Cl


RN 433938-50-2 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(trifluoromethoxy)phenyl]hydroxyacetyl]-2-

Serial No.:10/516,423

azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-,
2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

-c1

RN 433938-88-6 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(2,2,2-trifluoroethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



—Cl

RN 433938-96-6 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(2,2-difluoroethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



—Cl

RN 433939-08-3 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(fluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—Cl

RN 433939-18-5 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(2-fluoroethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—Cl

RN 433939-26-5 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—Cl

RN 433939-38-9 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-(difluoromethoxy)-5-fluorophenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—F

RN 433939-47-0 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-bromo-5-(fluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—Br

RN 433939-55-0 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-bromo-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

Br

RN 433939-57-2 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(2,2-difluoroethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433939-58-3 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(2-fluoroethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433939-99-2 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]-3,5-difluorophenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B


Cl

RN 433940-15-9 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]-2,5-difluorophenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA

INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—Cl


IT 433938-22-8P 433938-34-2P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of mandeloylazetidinecarboxamides as thrombin inhibitors)
 RN 433938-22-8 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[4-[(hydroxyamino)iminomethyl]phenyl]methyl-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 433938-34-2 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[2,5-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 5 WPIX COPYRIGHT 2009 THOMSON REUTERS on STN
 ACCESSION NUMBER: 2003-402841 [38] WPIX
 CROSS REFERENCE: 2002-599409; 2001-434941
 DOC. NO. CPI: C2003-107107 [38]
 TITLE: New N-(4-amidino-2,6-difluorobenzyl)-1-(2-(3-chloro-5-difluoromethoxyphenyl)-2-hydroxyacetyl)-2-azetidinecarboxamide compounds useful as thrombin inhibitors
 DERWENT CLASS: B03
 INVENTOR: INGHARDT T; JOHANSSON A; SVENSSON A; ANDERS J; ARNE S; TORD I
 PATENT ASSIGNEE: (ASTR-C) ASTRAZENECA AB; (INGH-I) INGHARDT T; (JOHA-I) JOHANSSON A; (SVEN-I) SVENSSON A
 COUNTRY COUNT: 100
 PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2003018551	A1	20030306	(200338)*	EN	67[0]	
EP 1423362	A1	20040602	(200436)	EN		
KR 2004029091	A	20040403	(200451)	KO		
AU 2002324410	A1	20030310	(200452)	EN		
BR 2002011847	A	20040908	(200462)	PT		
US 20040242492	A1	20041202	(200480)	EN		
HU 2004001189	A2	20041228	(200506)	HU		
JP 2005504057	W	20050210	(200511)	JA	103	
CN 1549808	A	20041124	(200516)	ZH		
MX 2004001825	A1	20040701	(200545)	ES		
ZA 2004001083	A	20050727	(200560)#	EN	76	
NZ 531109	A	20060331	(200626)	EN		
US 7056907	B2	20060606	(200638)	EN		
CN 1301969	C	20070228	(200749)	ZH		
MX 247328	B	20070718	(200856)	ES		
AU 2002324410	B2	20080424	(200858)	EN		
NO 326496	B1	20081215	(200919)	NO		
RU 2341516	C2	20081220	(200919)	RU		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003018551 A1		WO 2002-SE1557	20020830
AU 2002324410 A1		AU 2002-324410	20020830
AU 2002324410 B2		AU 2002-324410	20020830
BR 2002011847 A		BR 2002-11847	20020830
CN 1549808 A		CN 2002-816924	20020830
CN 1301969 C		CN 2002-816924	20020830
EP 1423362 A1		EP 2002-759050	20020830
NZ 531109 A		NZ 2002-531109	20020830
EP 1423362 A1 PCT Application		WO 2002-SE1557	20020830
BR 2002011847 A PCT Application		WO 2002-SE1557	20020830
US 20040242492 A1 PCT Application		WO 2002-SE1557	20020830
HU 2004001189 A2 PCT Application		WO 2002-SE1557	20020830
JP 2005504057 W PCT Application		WO 2002-SE1557	20020830
MX 2004001825 A1 PCT Application		WO 2002-SE1557	20020830
NZ 531109 A PCT Application		WO 2002-SE1557	20020830
US 7056907 B2 PCT Application		WO 2002-SE1557	20020830
MX 247328 B PCT Application		WO 2002-SE1557	20020830
JP 2005504057 W		JP 2003-523215	20020830
HU 2004001189 A2		HU 2004-1189	20020830
ZA 2004001083 A		ZA 2004-1083	20040210
MX 2004001825 A1		MX 2004-1825	20040226
MX 247328 B		MX 2004-1825	20040226
US 20040242492 A1		US 2004-487805	20040226
US 7056907 B2		US 2004-487805	20040226
KR 2004029091 A		KR 2004-702939	20040227
NO 326496 B1 PCT Application		WO 2002-SE1557	20020830
RU 2341516 C2 PCT Application		WO 2002-SE1557	20020830
RU 2341516 C2		RU 2004-103625	20020830
NO 326496 B1		NO 2004-813	20040224

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
EP 1423362	A1	Based on	WO 2003018551	A
AU 2002324410	A1	Based on	WO 2003018551	A
BR 2002011847	A	Based on	WO 2003018551	A
HU 2004001189	A2	Based on	WO 2003018551	A
JP 2005504057	W	Based on	WO 2003018551	A
MX 2004001825	A1	Based on	WO 2003018551	A
NZ 531109	A	Based on	WO 2003018551	A
US 7056907	B2	Based on	WO 2003018551	A
MX 247328	B	Based on	WO 2003018551	A
AU 2002324410	B2	Based on	WO 2003018551	A
NO 326496	B1	Previous Publ	NO 2004000813	A
RU 2341516	C2	Based on	WO 2003018551	A

PRIORITY APPLN. INFO: WO 2001-SE2657 20011130
SE 2001-2921 20010830
SE 2001-2657 20011130
ZA 2004-1083 20040210
WO 2001-SE2 20011130

AB WO 2003018551 A1 UPAB: 20090327

NOVELTY - N-(4-Amidino-2,6-difluorobenzyl)-1-(2-(3-chloro-5-difluoromethoxyphenyl)-2-hydroxyacetyl)-2-azetidinecarboxamide compounds (I) are new.

DETAILED DESCRIPTION - N-(4-amidino-2,6-difluorobenzyl)-1-(2-(3-chloro-5-difluoromethoxyphenyl)-2-hydroxyacetyl)-2-azetidinecarboxamide compounds of formula (I) and their pharmaceutically acceptable derivatives are new.

R1 = H, OR2 or COOR3;

R2 = H, 1-10C alkyl, QAr or QOAr;

Q = 1-3C alkylene optionally interrupted by O;

Ar = aryl optionally substituted by halo, Ph, Me, OMe, halophenyl, halomethyl or halomethoxy; and

R3 = 1-10C alkyl (optionally interrupted by O), QAr or QOAr.

INDEPENDENT CLAIMS are also included for:

(1) a method for treating a condition where thrombin inhibition or anticoagulant therapy is indicated, comprising administering a compound (I); and

(2) preparation of (I).

ACTIVITY - Anticoagulant; Thrombolytic.

MECHANISM OF ACTION - Thrombin inhibitor.


In an assay comprising incubating an inhibitor solution comprising 1-((3-chloro-5-difluoromethoxy-phenyl)-hydroxy-acetyl)-azetidine-2- carboxylic acid 4-carbamimidoyl-2,6-difluoro-benzylamide (Ia) (25 microliters) with plasma for 3 minutes, adding human thrombin in buffer solution (pH 7.4, 25 microliters, 4 NIH units.ml) and measuring the clotting time, (Ia) doubled clotting time with an IC50 of 0.02 microM.

USE - (I) Are useful for treating conditions where thrombin inhibition or anticoagulant therapy is indicated, especially thrombosis and hypercoagulability in blood and tissues (all claimed).

AN.S DCR-691165

CN.S 1-[(3-Chloro-5-difluoromethoxy-phenyl)-hydroxy-acetyl]-azetidine-2-carboxylic acid 4-carbamimidoyl-2,6-difluoro-benzylamide


SDCN RAA2A0



AN.S DCR-709336

CN.S 1-[(3-Chloro-5-difluoromethoxy-phenyl)-hydroxy-acetyl]-azetidine-2-carboxylic acid 2,6-difluoro-4-(N-methoxy-carbamimidoyl)-benzylamide


SDCN RAACW2



AN.S DCR-709337

CN.S 1-[(3-Chloro-5-difluoromethoxy-phenyl)-hydroxy-acetyl]-azetidine-2-carboxylic acid 2,6-difluoro-4-(N-hydroxycarbamimidoyl)-benzylamide

SDCN RAACW3



Structure Search

=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 14:58:49 ON 22 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 May 2009 VOL 150 ISS 22
FILE LAST UPDATED: 21 May 2009 (20090521/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.


CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D STAT QUE L7
L2 STR



Structure attributes must be viewed using STN Express query preparation.

L4 150 SEA FILE=REGISTRY SSS FUL L2
L7 15 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L4

=> FILE WPIX

FILE 'WPIX' ENTERED AT 14:58:59 ON 22 MAY 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE LAST UPDATED: 17 MAY 2009 <20090517/UP>
MOST RECENT UPDATE: 200931 <200931/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.3 million chemical structures in DCR <<<

>>> IPC, ECLA and US National Classifications have been updated
with reclassifications to March 15th, 2009.
F-Term and FI-Term original classifications are current and
reclassification will commence in June.
No update date (UP) has been created for the reclassified
documents, but they can be identified by
specific update codes (see HELP CLA for details)<<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:

http://www.stn-international.com/stn_guide.html

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

<http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/>


EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:

http://www.stn-international.com/DWPIAnaVist2_0608.html

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

'BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> D STAT QUE L16
L2 STR



Structure attributes must be viewed using STN Express query preparation.

L15 80 SEA FILE=WPIX SSS FUL L2
L16 11 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L15/DCR

=> DUP REM L7 L16
FILE 'HCAPLUS' ENTERED AT 14:59:09 ON 22 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 14:59:09 ON 22 MAY 2009

COPYRIGHT (C) 2009 THOMSON REUTERS

PROCESSING COMPLETED FOR L7

PROCESSING COMPLETED FOR L16

L21 16 DUP REM L7 L16 (10 DUPLICATES REMOVED)

ANSWERS '1-15' FROM FILE HCAPLUS

ANSWER '16' FROM FILE WPIX

=> D IBIB ED ABS HITSTR 1-15; D IBIB AB HITSTR 16

L21 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2009:264552 HCAPLUS Full-text

DOCUMENT NUMBER: 150:290757

TITLE: Extended release pharmaceutical of a thrombin inhibitor

INVENTOR(S): Abrahamsson, Bertil Sven Inge; Abrahamson Alami, Susanna Johanna; Bagger-Joergensen, Haakan Lars; Cullberg, Marie Christine Sindeby; Hjaertstam, Lars Johan Pontus De Verdier; Nilsson, Susanne Anette

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 33pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009027745	A1	20090305	WO 2008-GB50755	20080829
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

US 20090061000 A1 20090305 US 2008-200549 20080828

PRIORITY APPLN. INFO.: US 2007-969188P P 20070831

ED Entered STN: 05 Mar 2009

GI



I


AB An extended release pharmaceutical formulation comprising as active ingredient I or a pharmaceutically acceptable salt (such as a sulfonic acid salt or besylate salt); and a pharmaceutically acceptable diluent or carrier; for use in providing a therapeutic antithrombotic effect while limiting drug-drug interactions with other concomitantly dosed drug/s, particularly those which are metabolized by CYP-450 enzymes. E.g., an extended release tablet contained I besylate, cellulose, Hypromellose, Na stearyl fumarate and ethanol for processing.

IT 433937-93-0 631916-97-7
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (extended release pharmaceutical of a thrombin inhibitor)

RN 433937-93-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 631916-97-7 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, benzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2


CRN 98-11-3

CMF C6 H6 O3 S



IT 433937-93-0D, sulfonic acid salts
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (extended release pharmaceutical of a thrombin inhibitor)
 RN 433937-93-0 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-
 (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 2
 ACCESSION NUMBER: 2008:702988 HCAPLUS Full-text
 DOCUMENT NUMBER: 149:38826
 TITLE: New crystalline forms of thrombin inhibitors and compositions thereof
 INVENTOR(S): Aaslund, Bengt Leonard; Bengtsson, Stefan; Bergman, Gudrun Anita; Hohlneicher, Ursula Renata Maria; Ymen, Bo Ingvar
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 55pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	----	-----	-----

Serial No.:10/516,423

WO 2008068475 A1 20080612 WO 2007-GB4640 20071205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


US 20080287413 A1 20081120 US 2007-950568 20071205

PRIORITY APPLN. INFO.:

ED Entered STN: 12 Jun 2008

US 2006-868752P P 20061206

GI



AB The invention relates to crystalline forms of the Compound A (I; R = H) and Compound B (I; R = Me), pharmaceutical compns. containing them, processes for obtaining them and their use for the treatment of a condition where inhibition of thrombin is required or desired. The compds. of the invention may be in a non-solvated form (such as an anhydrate) or in the form of solvate, e.g., isopropanolate. Thus, Compound A in Et acetate was evaporated to a gel, isopropanol and some seeds of Compound A were added, and the mixture was left to stir overnight to obtain Compound A crystalline anhydrate. Microcryst. cellulose cores were coated in a fluidized bed with an aqueous solution of Compound A crystalline anhydrate/HPMC, followed by an ethanolic solution of Et cellulose/hydroxypropyl cellulose. The pellets were finally coated with Eudragit L30D to obtain enteric-coated pellets.


IT 433937-73-6P 433937-93-0P

RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation and formulations of crystalline forms of thrombin inhibitors)

RN 433937-73-6 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-93-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(imino(methoxyamino)methyl)phenyl]methyl]-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.



IT 1031700-40-9P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and formulations of crystalline forms of thrombin inhibitors)

RN 1031700-40-9 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-, compd. with 2-propanol (3:1), (2S)-(CA INDEX NAME)

CM 1

CRN 433937-73-6

CMF C21 H21 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 67-63-0

CMF C3 H8 O



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2007:463352 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 146:462511

TITLE: Fibrin targeted therapeutics, particularly peptidomimetics, their preparation and use in the treatment of thromboembolism, infection, and cancer

INVENTOR(S): McMurry, Thomas J.; Kolodziej, Andrew; Carpenter, Alan P., Jr.; Jones, Simon; Graham, Philip; Looby, Richard; Shrikumar, A. Nair; Wang, Xifang; Overoye-Chen, Kirsten; Barrett, John A.

PATENT ASSIGNEE(S): Epix Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 136pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007047608	A2	20070426	WO 2006-US40430	20061016
WO 2007047608	A3	20070920		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,			

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20070111947 A1 20070517 US 2006-581677 20061016
 PRIORITY APPLN. INFO.: US 2005-726632P P 20051014
 US 2006-800152P P 20060512

OTHER SOURCE(S): MARPAT 146:462511

ED Entered STN: 27 Apr 2007

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is related to hybrid mols. of formula [D]_m-[L]_n-[F]_q [I; wherein [D] comprises a bioactive moiety for treating thromboembolism, infection, and cancer; [L] comprises a linker moiety; [F] comprises a fibrin-targeting moiety selected from a peptide, peptidomimetic, or a small mol.; m, q = independently 1-20; n = 0-20]. I can provide enhanced efficacy and reduced systemic toxicity relative to a corresponding non-targeted bioactive mol. Thus, a paclitaxel-fibrin binding peptide conjugate II was prepared using paclitaxel, succinyl anhydride, and peptide III (H-R). II in a dose-responsive manner caused a significant decrease in the number of cancer cells in lung and breast cancer lines and in the number of smooth muscle and endothelial cells.


IT 433937-93-0DP, bioconjugate with fibrin-targeting moieties
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fibrin targeted therapeutic agents useful in treatment of thromboembolism, infection, and cancer)

RN 433937-93-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



L21 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2006:1354313 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 146:100732

TITLE: Preparation of crystalline N,N'-disubstituted oxabispindines and their use as cardiovascular agents.

INVENTOR(S): Juppo, Anne; Steele, Gerald

Serial No.:10/516,423

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
 SOURCE: PCT Int. Appl., 60pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006137772	A1	20061228	WO 2006-SE692	20060612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: SE 2005-1428 A 20050620
 OTHER SOURCE(S): MARPAT 146:100732
 ED Entered STN: 28 Dec 2006
 GI



R4BCR2R3A' DNHCO2R1 I


AB Crystalline material consisting essentially of title compds. [I; D = alkylene; R1 = (substituted) alkyl; R2 = H, halo, alkyl, OR5, ENR6R6; R3 = H, alkyl; R2R3 = O; R4 = (substituted) Ph, pyridyl; R5 = H, alkyl, aryl(alkyl), heteroaryl(alkyl), etc.; R6 = H, alkyl, aryl(alkyl), heteroaryl(alkyl), C:(NH)NH2, etc.; R7 = H, alkyl, aryl(alkyl), etc.; A = bond, J, JNR10a, JO, JSO2NR10b, etc.; B = Z[[C(O)]aCH(R11a)]b, Z[C(O)]cNR11b, ZO, etc.; J = (substituted) (interrupted) alkylene; a, b, c = 0, 1; R10a, R10b = H, alkyl; R11a = H; R11b = H, alkyl; R4R11a, R4R11b = (interrupted) alkylene; with provisos, having a surface area of <0.7 m2/g], was prepared Thus, tert-Bu 2-[7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxo-3,7-diazabicyclo[3.3.1]non-3-yl]ethylcarbamate (II) (preparation given) was recrystd. from diisopropyl ether/isopropanol (10:2 volume/volume) to give 91% crystalline II having a mean surface area of 0.1659 m2/g.

IT 917904-13-3 917904-15-5
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (coadministration; preparation of crystalline N,N'-disubstituted oxabispidines
 and their use as cardiovascular agents)

RN 917904-13-3 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl)methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 917904-15-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 5
 ACCESSION NUMBER: 2003:972051 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 140:27752
 TITLE: [Chloro(difluoromethoxy)phenyl]hydroxyacetylazetidinecarboxamide derivative salts preparation as prodrugs
 INVENTOR(S): Ahlqvist, Matti; Bohlin, Martin; Inghardt, Tord; Lundblad, Anita; Sigfridsson, Carl-Gustaf
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
 SOURCE: PCT Int. Appl., 108 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101957	A1	20031211	WO 2003-SE859	20030527

Serial No.:10/516,423

OTHER SOURCE(S): MARPAT 140:27752
ED Entered STN: 14 Dec 2003
GI



I

AB There is provided pharmaceutically-acceptable acid addition salts of compds. of such as I. I was prepared along with two other similar compds. Salts of I prepared include the ethanesulfonate and benzenesulfonate. The salts are useful as prodrugs of competitive inhibitors of trypsin-like proteases, such

as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

IT 433937-93-0P 433938-09-1P 433938-32-0P

433938-43-3P 433939-99-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

([chloro(difluoromethoxy)phenyl]hydroxyacetylazetidinecarboxamide derivative salts preparation as prodrugs)

RN 433937-93-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-09-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-32-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-43-3 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—Cl

RN 433939-99-2 HCAPLUS


CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]-3,5-difluorophenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- C1

IT	631916-71-7P	631916-73-9P	631916-75-1P
	631916-76-2P	631916-77-3P	631916-79-5P
	631916-81-9P	631916-83-1P	631916-91-1P
	631916-97-7P	631917-18-5P	631917-19-6P
	631917-20-9P	631917-21-0P	631917-22-1P
	631917-23-2P	631917-24-3P	631917-25-4P
	631917-27-6P	631917-28-7P	631917-29-8P
	631917-30-1P	631917-45-8P	633315-91-0P
	633315-92-1P	633315-93-2P	633315-95-4P
	RL: SPN (Synthetic preparation); PREP (Preparation)		
	([chloro(difluoromethoxy)phenyl]hydroxyacetylazetidinecarboxamide		
	derivative salts preparation as prodrugs)		
RN	631916-71-7	HCAPLUS	
CN	Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-,		
	(1S,4R)-, compd. with (2S)-1-[(2R)-[3-chloro-5-		
	(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-		
	[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)		
	(9CI) (CA INDEX NAME)		
CM	1		
CRN	433937-93-0		
CMF	C22	H23	C1 F2 N4 O5




CM 2

CRN 3144-16-9

CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).



RN 631916-73-9 HCAPLUS


CN Sulfamic acid, cyclohexyl-, compd. with
(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1


CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2
 CRN 100-88-9
 CMF C6 H13 N O3 S



RN 631916-75-1 HCAPLUS
 CN Phosphoric acid, dimethyl ester, compd. with
 (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (9CI) (CA INDEX NAME)

CM 1
 CRN 433937-93-0
 CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2
 CRN 813-78-5
 CMF C2 H7 O4 P




RN 631916-76-2 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-
 hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-,
 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



RN 631916-77-3 HCAPLUS


CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631916-79-5 HCAPLUS


CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1), monohydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631916-81-9 HCAPLUS

Serial No.:10/516,423


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 631916-83-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrochloride (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 631916-91-1 HCAPLUS


CN Ethanesulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]phenyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 594-45-6

CMF C2 H6 O3 S



RN 631916-97-7 HCAPLUS

Serial No.:10/516,423


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, benzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



RN 631917-18-5 HCAPLUS


CN 1-Propanesulfonic acid, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 5284-66-2

CMF C3 H8 O3 S



RN 631917-19-6 HCAPLUS


CN 1-Butanesulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 2386-47-2

CMF C4 H10 O3 S



RN 631917-20-9 HCAPLUS


CN Ethanesulfonic acid, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 594-45-6

CMF C2 H6 O3 S




RN 631917-21-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, benzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2
CRN 98-11-3
CMF C6 H6 O3 S



RN 631917-22-1 HCAPLUS
CN Sulfamic acid, cyclohexyl-, compd. with
(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1
CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 100-88-9

CMF C6 H13 N O3 S



RN 631917-23-2 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 631917-24-3 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-

Serial No.:10/516,423

hydroxyacetyl]-N-[[2,6-difluoro-4-
[imino(methoxyamino)methyl]phenyl]methyl]-, hydrobromide (1:1), (2S)- (CA
INDEX NAME)

Absolute stereochemistry.




RN 631917-25-4 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-
hydroxyacetyl]-N-[[2,6-difluoro-4-
[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-,
4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1


CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 104-15-4
CMF C7 H8 O3 S




RN 631917-27-6 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, sulfate (2:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 631917-28-7 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 631917-29-8 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 7697-37-2
CMF H N O3



RN 631917-30-1 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-(imino(methoxyamino)methyl)phenyl]methyl]-, hydrochloride (1:1), (2S)-(CA INDEX NAME)

Absolute stereochemistry.




RN 631917-45-8 HCAPLUS
CN 1,5-Naphthalenedisulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-(imino(methoxyamino)methyl)phenyl]methyl]-2-azetidinecarboxamide (1:2) (CA INDEX NAME)

CM 1

CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 81-04-9

CMF C10 H8 O6 S2



RN 633315-91-0 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, (2Z)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 633315-92-1 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, phosphate (3:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 633315-93-2 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, compd. with 1,2-benzisothiazol-3(2H)-one 1,1-dioxide, sodium salt (1:1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 128-44-9

CMF C7 H5 N O3 S . Na



● Na

RN 633315-95-4 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[(2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl)methyl]-, (2S)-, mononaphthalenesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 25155-19-5
 CMF C10 H8 O3 S
 CCI IDS

D1-SO₃H

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 6
 ACCESSION NUMBER: 2003:9/2050 HCAPLUS Full-text
 DOCUMENT NUMBER: 140:2/751
 TITLE: Preparation of azetidinybenzamidines and related
 compounds for combination therapy of arrhythmia or
 coagulation controlled complications thereof.
 INVENTOR(S): Roth-Rosendahl, Ann-Charlotte; Svernhage, Elisabeth
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
 SOURCE: PCT Int. Appl., 160 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101956	A1	20031211	WO 2003-SE854	20030527
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2486110	A1	20031211	CA 2003-2486110	20030527
AU 2003232711	A1	20031219	AU 2003-232711	20030527
BR 2003011138	A	20050301	BR 2003-11138	20030527
EP 1513807	A1	20050316	EP 2003-756136	20030527
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1656066	A	20050817	CN 2003-811734	20030527
JP 2005532345	T	20051027	JP 2004-509650	20030527
NO 2004004673	A	20041207	NO 2004-4673	20041028
ZA 2004008787	A	20051020	ZA 2004-8787	20041029
IN 2004DN03380	A	20050401	IN 2004-DN3380	20041101
MX 2004011910	A	20050331	MX 2004-11910	20041129

US 20060052314
PRIORITY APPLN. INFO.:


A1 20060309

US 2005-516426
SE 2002-1662
WO 2003-SE854

20050628
A 20020531
W 20030527

ED Entered STN: 14 Dec 2003

GI



AB A combination product comprising: (a) a compound of claim 1 in WO 02/44145 or a pharmaceutically-acceptable derivative thereof; and (b) (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A [4-[[3-[7-(3,3-dimethyl-2-oxobutyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]propyl]amino]benzonitrile] or B [tert-Bu 2-[7-[3-(4-cyanoanilino)propyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethylcarbamate] or C [tert-Bu 2-[7-[4-(4-cyanophenyl)butyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethylcarbamate] or D [tert-Bu 2-[7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethylcarbamate] or pharmaceutically acceptable salts thereof in admixt. with a pharmaceutically acceptable adjuvant, diluent or carrier, is claimed. Thus, title compound (I) (multistep preparation given) showed an IC50 TT value of <0.02 μ M.


IT 433937-78-1 433937-98-5 433938-01-3
433938-04-6 433938-07-9 433938-10-4
433938-13-7 433938-16-0 433938-18-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of azetidinybenzamidines and related compds. for combination therapy of arrhythmia or coagulation controlled complications thereof)

RN 433937-78-1 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-98-5 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2,2,2-trifluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-01-3 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2,2-difluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-04-6 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(fluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-07-9 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-10-4 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2-fluoro-1-(fluoromethyl)ethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-13-7 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-(difluoromethoxy)-5-fluorophenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-16-0 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-bromo-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-18-2 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-bromo-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 433937-72-5P 433937-73-6P 433937-74-7P
 433937-76-9P 433937-77-0P 433937-79-2P
 433937-80-5P 433937-81-6P 433937-93-0P
 433937-99-6P 433938-00-2P 433938-02-4P
 433938-03-5P 433938-05-7P 433938-06-8P

433938-08-0P 433938-09-1P 433938-11-5P
 433938-12-6P 433938-14-8P 433938-15-9P
 433938-17-1P 433938-19-3P 433938-20-6P
 433938-21-7P 433938-22-8P 433938-30-8P
 433938-31-9P 433938-32-0P 433938-33-1P
 433938-34-2P 433938-35-3P 433938-36-4P
 433938-37-5P 433938-51-3P 433938-52-4P
 433938-53-5P 433938-54-6P 433938-55-7P
 433938-56-8P 433938-57-9P 433938-58-0P
 433938-59-1P 433938-60-4P 433938-61-5P
 433938-62-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azetidinybenzamidines and related compds. for combination therapy of arrhythmia or coagulation controlled complications thereof)

RN 433937-72-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(cyclobutyloxy)amino]iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-73-6 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-74-7 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-76-9 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-77-0 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433937-79-2 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-78-1

CMF C21 H20 Cl F3 N4 O4

Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 433937-80-5 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-81-6 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino[(5-methyl-3-isoxazolyl)methoxy]amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-93-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433937-99-6 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Serial No.:10/516,423


[3-chloro-5-(2,2,2-trifluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-98-5

CMF C22 H22 Cl F3 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-00-2 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2,2,2-trifluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-(imino(methoxyamino)methyl)phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-02-4 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2,2-difluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-01-3

CMF C22 H23 Cl F2 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-03-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2,2-difluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-05-7 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(fluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-04-6

CMF C21 H22 Cl F N4 O4

Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 433938-06-8 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(fluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-08-0 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-07-9

CMF C22 H24 Cl F N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-09-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-11-5 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-10-4

CMF C23 H25 Cl F2 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 433938-12-6 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-[2-fluoro-1-

Serial No.:10/516,423

(fluoromethyl)ethoxy|phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-14-8 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-(difluoromethoxy)-5-fluorophenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-13-7

CMF C21 H21 F3 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-15-9 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-(difluoromethoxy)-5-fluorophenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-17-1 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-bromo-5-(fluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-16-0

CMF C21 H22 Br F N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 433938-19-3 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-bromo-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-18-2
 CMF C21 H21 Br F2 N4 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 433938-20-6 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-bromo-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-21-7 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2,2-difluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-22-8 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-30-8 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)-3-fluorophenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-31-9 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)-2,6-difluorophenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-32-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-33-1 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)-2,5-difluorophenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-34-2 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,5-difluoro-4-imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-35-3 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(ethoxyamino)iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-36-4 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(propoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-37-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(1-methylethoxy)amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-51-3 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(3-pyridinylmethoxy)amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-52-4 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(2-methylpropoxy)amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-53-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(ethoxyamino)iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-54-6 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(phenylmethoxy)amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-55-7 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(cyclohexyloxy)amino]iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-56-8 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(cyclobutyloxy)amino]iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-57-9 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino[2-[3-(trifluoromethyl)phenoxy]ethoxy]amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-58-0 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-[[[(4-chlorophenyl)methoxy]amino]iminomethyl]phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-59-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino[(3-methoxyphenyl)methoxy]amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-60-4 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-[[[(2-bromophenyl)methoxy]amino]iminomethyl]phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-61-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[[imino[(4-methylphenyl)methoxy]amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-62-6 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[[imino[(1-propylbutoxy)amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 433938-43-3P 433938-50-2P 433938-88-6P
 433938-96-6P 433939-08-3P 433939-18-5P
 433939-26-5P 433939-38-9P 433939-47-0P
 433939-55-0P 433939-57-2P 433939-58-3P
 433939-99-2P 433940-15-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of azetidinybenzamidines and related compds. for combination
 therapy of arrhythmia or coagulation controlled complications thereof)
 RN 433938-43-3 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-
 (difluoromethoxy)phenyl]hydroxyacetyl]-2-
 azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-,
 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

Cl

RN 433938-50-2 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-

(trifluoromethoxy)phenyl]hydroxyacetyl]-2-
azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-,
2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

Cl

RN 433938-88-6 HCAPLUS
CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(2,2,2-trifluoroethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



—Cl

RN 433938-96-6 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(2,2-difluoroethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



—Cl

RN 433939-08-3 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(fluoromethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—Cl

RN 433939-18-5 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(2-fluoroethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—Cl

RN 433939-26-5 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

-Cl

RN 433939-38-9 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-(difluoromethoxy)-5-fluorophenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




—F

RN 433939-47-0 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-bromo-5-(fluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




—Br

RN 433939-55-0 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-bromo-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B



RN 433939-57-2 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(2,2-difluoroethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433939-58-3 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(2-fluoroethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433939-99-2 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]-3,5-difluorophenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B


Cl

RN 433940-15-9 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]-2,5-difluorophenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L21 ANSWER 7 OF 16 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 7
 ACCESSION NUMBER: 2003:971865 HCAPLUS Full-text
 DOCUMENT NUMBER: 140:31486
 TITLE: Modified-release pharmaceutical formulation containing cardiovascular agents
 INVENTOR(S): Magnusson, Anders; Thune, Mikael
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
 SOURCE: PCT Int. Appl., 115 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101424	A1	20031211	WO 2003-SE858	20030527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				

Serial No.:10/516,423

CA 2485535	A1	20031211	CA 2003-2485535	20030527
AU 2003232870	A1	20031219	AU 2003-232870	20030527
EP 1513495	A1	20050316	EP 2003-728205	20030527
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011460	A	20050329	BR 2003-11460	20030527
CN 1655761	A	20050817	CN 2003-812492	20030527
CN 100402025	C	20080716		
JP 2005536472	T	20051202	JP 2004-508782	20030527
NZ 536621	A	20061027	NZ 2003-536621	20030527
NZ 549176	A	20071221	NZ 2003-549176	20030527
CN 101264051	A	20080917	CN 2008-10099130	20030527
RU 2352323	C2	20090420	RU 2004-132856	20030527
NO 2004004767	A	20050225	NO 2004-4767	20041103
IN 2004DN03415	A	20090227	IN 2004-DN3415	20041103
ZA 2004009234	A	20050712	ZA 2004-9234	20041117
MX 2004011914	A	20050331	MX 2004-11914	20041129
US 20050171083	A1	20050804	US 2004-516420	20041129
US 7202236	B2	20070410		
IN 2006DN06241	A	20070831	IN 2006-DN6241	20061025
US 20080050437	A1	20080228	US 2007-716021	20070309
PRIORITY APPLN. INFO.:			SE 2002-1659	A 20020531
			CN 2003-812492	A3 20030527
			NZ 2003-536621	A3 20030527
			WO 2003-SE858	W 20030527
			IN 2004-DN3415	A3 20041103
			US 2004-516420	A1 20041129

OTHER SOURCE(S): MARPAT 140:31486
 ED Entered STN: 14 Dec 2003
 GI



I

AB Disclosed is a modified-release pharmaceutical composition comprising, as active ingredient, a compound of formula I (R1 = Cl-2 alkyl substituted by one or more fluoro substituents; R2 = H, OH, OMe, OEt; and n = 0-2) or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier. The formulation may only contain L-carrageenan and a neutral gelling polymer when the compound of formula I is in the form of a salt; such formulations being of use for the treatment of a cardiovascular disorder. A compound Ph(3-Cl)(5-OCHF2)-(R)-CH(OH)C(O)-(S)-Aze-Pab(OMe) esylate salt was prepared, its 50.5 mg was combined with hydroxypropyl Me cellulose 200, and sodium stearyl fumarate 2.5 mg to obtain a modified-release tablets.

IT 631916-71-7P 631916-72-8P 631916-73-9P
 631916-74-0P 631916-75-1P 631916-76-2P
 631916-77-3P 631916-79-5P 631916-80-8P
 631916-81-9P 631916-83-1P 631916-85-3P
 631916-86-4P 631916-87-5P 631916-89-7P
 631916-91-1P 631916-92-2P 631916-93-3P
 631916-94-4P 631916-95-5P 631916-96-6P
 631916-97-7P 631916-98-8P 631917-01-6P
 631917-03-8P 631917-04-9P 631917-05-0P
 631917-06-1P 631917-07-2P 631917-09-4P
 631917-11-8P 631917-13-0P 631917-15-2P
 631917-17-4P 631917-20-9P 631917-21-0P
 631917-22-1P 631917-23-2P 631917-24-3P
 631917-25-4P 631917-26-5P 631917-27-6P
 631917-28-7P 631917-29-8P 631917-30-1P
 631917-31-2P 631917-32-3P 631917-33-4P
 631917-34-5P 631917-35-6P 631917-36-7P
 631917-37-8P 631917-39-0P 631917-40-3P
 631917-42-5P 631917-43-6P 631917-44-7P
 631917-45-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (modified-release pharmaceutical formulation containing cardiovascular agents)

RN 631916-71-7 HCAPLUS


CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 3144-16-9

CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).




RN 631916-72-8 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0
 CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.




RN 631916-73-9 HCAPLUS
 CN Sulfamic acid, cyclohexyl-, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 100-88-9
CMF C6 H13 N O3 S




RN 631916-74-0 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-(methoxyamino)methyl]phenyl]methyl]-, (2S)-, phosphate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-38-2

CMF H3 O4 P



RN 631916-75-1 HCAPLUS


CN Phosphoric acid, dimethyl ester, compd. with
(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 813-78-5

CMF C2 H7 O4 P



RN 631916-76-2 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-
hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-,

Serial No.:10/516,423


4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



RN 631916-77-3 HCAPLUS


CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631916-79-5 HCAPLUS


CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1), monohydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631916-80-8 HCAPLUS


CN 2-Azetidinedicarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, compd. with 1,2-benzisothiazol-3(2H)-one 1,1-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 81-07-2

CMF C7 H5 N O3 S



RN 631916-81-9 HCAPLUS


CN 2-Azetidinedicarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 631916-83-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrochloride (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 631916-85-3 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrobromide (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 631916-86-4 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, sulfate (2:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 631916-87-5 HCAPLUS
 CN 1,2-Ethanedisulfonic acid, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 110-04-3

CMF C2 H6 O6 S2




RN 631916-89-7 HCAPLUS
 CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-,
 (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-
 hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-
 azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 5872-08-2

CMF C10 H16 O4 S



RN 631916-91-1 HCAPLUS


CN Ethanesulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl)methyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 594-45-6

CMF C2 H6 O3 S



RN 631916-92-2 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 7697-37-2

CMF H N O3



RN 631916-93-3 HCAPLUS


CN Benzenesulfonic acid, 2,5-dimethyl-, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 609-54-1

CMF C8 H10 O3 S



RN 631916-94-4 HCAPLUS


CN Benzenesulfonic acid, 2,4,6-trimethyl-, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl)methyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1


CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2
CRN 3453-83-6
CMF C9 H12 O3 S



RN 631916-95-5 HCAPLUS
CN 1,5-Naphthalenedisulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:2)
(CA INDEX NAME)

CM 1
CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2
CRN 81-04-9
CMF C10 H8 O6 S2



RN 631916-96-6 HCAPLUS
CN Naphthalenesulfonic acid, compd. with
(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-

Serial No.:10/516,423


[imino(methoxyamino)methyl]phenyl)methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 25155-19-5

CMF C10 H8 O3 S

CCI IDS



D1-SO₃H

RN 631916-97-7 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, benzenesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.

Serial No.:10/516,423



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



RN 631916-98-8 HCAPLUS


CN D-Glutamic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 6893-26-1

CMF C5 H9 N O4

Absolute stereochemistry.



RN 631917-01-6 HCAPLUS


CN L-Glutamic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-86-0

CMF C5 H9 N O4

Absolute stereochemistry.



RN 631917-03-8 HCAPLUS


CN Glutamic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

Serial No.:10/516,423


CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 617-65-2
CMF C5 H9 N O4




RN 631917-04-9 HCAPLUS
CN L-Arginine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-(imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 631917-05-0 HCAPLUS


CN Glycine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 56-40-6

CMF C2 H5 N O2



RN 631917-06-1 HCAPLUS


CN Benzoic acid, 2-hydroxy-, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 69-72-7

CMF C7 H6 O3



RN 631917-07-2 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 631917-09-4 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 631917-11-8 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 77-92-9

CMF C6 H8 O7



RN 631917-13-0 HCAPLUS
 CN Butanedioic acid, 2-hydroxy-, (2S)-(2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)


CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.

CMF C4 H6 O5



RN 631917-17-4 HCAPLUS


CN D-Gluconic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 526-95-4

CMF C6 H12 O7

Absolute stereochemistry.




RN 631917-20-9 HCAPLUS

CN Ethanesulfonic acid, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[(imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1


CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 594-45-6
CMF C2 H6 O3 S




RN 631917-21-0 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, benzenesulfonate (1:1)
(CA INDEX NAME)

CM 1

CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2
CRN 98-11-3
CMF C6 H6 O3 S




RN 631917-22-1 HCAPLUS
CN Sulfamic acid, cyclohexyl-, compd. with
(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-(imino(methoxyamino)methyl)phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1
CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2
CRN 100-88-9
CMF C6 H13 N O3 S



RN 631917-23-2 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-

Serial No.:10/516,423


[imino(methoxyamino)methyl]phenyl)methyl]-, (2S)-, sulfate (1:1) (CA
INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-93-9


CMF H2 O4 S



RN 631917-24-3 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-
[imino(methoxyamino)methyl]phenyl)methyl]-, hydrobromide (1:1), (2S)- (CA
INDEX NAME)

Absolute stereochemistry.



● HBr


RN 631917-25-4 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



RN 631917-26-5 HCAPLUS
 CN 2-Naphthalenesulfonic acid, (2S)-compd. with

Serial No.:10/516,423


1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 120-18-3

CMF C10 H8 O3 S



RN 631917-27-6 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, sulfate (2:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 631917-28-7 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 631917-29-8 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2


CRN 7697-37-2

CMF H N O3



RN 631917-30-1 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrochloride (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 631917-31-2 HCAPLUS


CN 1,2-Ethanedisulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-
difluoro-4-[(methoxyamino)methyl]phenyl]methyl]-2-
azetidinecarboxamide (1:2) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 110-04-3

CMF C2 H6 O6 S2



RN 631917-32-3 HCAPLUS

CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-,
(1S,4R)-, compd. with (2S)-1-[(2R)-[3-chloro-5-
(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-

Serial No.:10/516,423


[imino(methoxyamino)methyl]phenyl)methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 3144-16-9

CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).



RN 631917-33-4 HCAPLUS


CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-,
(2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-
hydroxyacetyl]-N-[[2,6-difluoro-4-
[imino(methoxyamino)methyl]phenyl)methyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 5872-08-2

CMF C10 H16 O4 S



RN 631917-34-5 HCAPLUS


CN Benzenesulfonic acid, 2,5-dimethyl-, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[(2,6-
difluoro-4-[(imino(methoxyamino)methyl]phenyl)methyl]-2-
azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 609-54-1

CMF C8 H10 O3 S



RN 631917-35-6 HCAPLUS


CN Benzenesulfonic acid, 2,4,6-trimethyl-, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-
 difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-
 azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 3453-83-6

CMF C9 H12 O3 S




RN 631917-36-7 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-
 hydroxyacetyl]-N-[[2,6-difluoro-4-
 [imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, compd. with
 1,2-benzisothiazol-3(2H)-one 1,1-dioxide (1:1) (CA INDEX NAME)

CM 1


CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 81-07-2
CMF C7 H5 N O3 S




RN 631917-37-8 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxycarbonyl)methyl]phenyl]methyl]-, (2S)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 631917-39-0 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, phosphate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 631917-40-3 HCAPLUS
 CN D-Glutamic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 6893-26-1

CMF C5 H9 N O4

Absolute stereochemistry.




RN 631917-42-5 HCAPLUS
 CN L-Arginine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2
CRN 74-79-3
CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 631917-43-6 HCAPLUS
CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[(imino(methoxyamino)methyl)phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1
CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631917-44-7 HCAPLUS


CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1), monohydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 631917-45-8 HCAPLUS
 CN 1,5-Naphthalenedisulfonic acid, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-
 difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-
 azetidinecarboxamide (1:2) (CA INDEX NAME)

CM 1

CRN 433938-32-0
 CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 81-04-9
 CMF C10 H8 O6 S2



IT 433937-93-0 433938-09-1 433938-32-0
 631917-18-5 631917-19-6 631917-46-9
 631917-47-0 631917-48-1
 RL THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (modified-release pharmaceutical formulation containing cardiovascular
 agents)
 RN 433937-93-0 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-
 hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-
 (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-09-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 433938-32-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 631917-18-5 HCAPLUS


CN 1-Propanesulfonic acid, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 5284-66-2

CMF C3 H8 O3 S



RN 631917-19-6 HCAPLUS

CN 1-Butanesulfonic acid, (2S)-compd. with


1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 2386-47-2

CMF C4 H10 O3 S



RN 631917-46-9 HCAPLUS


CN 1-Propanesulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[(2,6-difluoro-4-{imino(methoxyamino)methyl}phenyl)methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 5284-66-2

CMF C3 H8 O3 S



RN 631917-47-0 HCAPLUS


CN 1-Butanesulfonic acid, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 2386-47-2

CMF C4 H10 O3 S




RN 631917-48-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, benzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-09-1
 CMF C23 H26 Cl F N4 O5

Absolute stereochemistry.



CM 2

CRN 98-11-3
 CMF C6 H6 O3 S



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 8 OF 16 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 8
 ACCESSION NUMBER: 2003:971864 HCAPLUS Full-text
 DOCUMENT NUMBER: 140:31485
 TITLE: Immediate-release pharmaceutical formulation of amidine compounds
 INVENTOR(S): Abrahamsen Alami, Susanna; Inghardt, Tord; Magnusson, Anders; Sigfridsson, Carl-Gustaf; Thune, Mikael
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
 SOURCE: PCT Int. Appl., 127 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101423	A1	20031211	WO 2003-SE857	20030527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,				

Serial No.:10/516,423

TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2485533	A1	20031211	CA 2003-2485533	20030527
AU 2003241239	A1	20031219	AU 2003-241239	20030527
BR 2003011363	A	20050301	BR 2003-11363	20030527
EP 1513496	A1	20050316	EP 2003-730964	20030527

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK


CN 1655760	A	20050817	CN 2003-812490	20030527
JP 2005536471	T	20051202	JP 2004-508781	20030527
NZ 536739	A	20061027	NZ 2003-536739	20030527
NZ 549273	A	20071221	NZ 2003-549273	20030527
RU 2351314	C2	20090410	RU 2004-133387	20030527
NO 2004004810	A	20050224	NO 2004-4810	20041104
IN 2004DN03468	A	20090213	IN 2004-DN3468	20041108
ZA 2004009237	A	20050714	ZA 2004-9237	20041117
MX 2004011943	A	20050331	MX 2004-11943	20041130
US 20060014734	A1	20060119	US 2005-516423	20050725
IN 2006DN06995	A	20070831	IN 2006-DN6995	20061122

PRIORITY APPLN. INFO.: SE 2002-1658 A 20020531
 NZ 2003-536739 A3 20030527
 WO 2003-SE857 W 20030527
 IN 2004-DN3468 A3 20041108

OTHER SOURCE(S): MARPAT 140:31485

ED Entered STN: 14 Dec 2003

GI



I

AB An immediate-release pharmaceutical formulation is provided comprising (a) as active ingredient, a compound of formula I (R1 = Cl-2 alkyl substituted by one or more fluoro substituents; R2 = H, OH, OMe, OEt; n = 0, 1, 2) or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable diluent or carrier. When the active ingredient is other than in the form of a salt, the formulation does not solely contain (i) a solution of one active ingredient and water, (ii) a solution of one active ingredient and DMSO, or (iii) a solution of one active ingredient in a mixture of ethanol/PEG 660 12-hydroxy stearate/water (5:5:90). Such formulations are used for the treatment of a cardiovascular disorder. For example, a solution was prepared by dissolving Compound A [I (R1 = CHF2, R2 = OMe, n = 0) (preparation given)] in a hydroxypropyl-β-cyclodextrin/water diluent (40:60 weight/weight%) (136 μmol Compound A to 1 mL diluent) and adjusting pH to 3.7 with HCl. The solubility of Compound A was at least 700 times higher in this vehicle compared to water alone.

IT 433937-73-6P 433937-74-7P 433937-93-0DP, salts
 with saccharinic acid 433937-93-0P 433938-07-9P


433938-09-1P 433938-21-7P 433938-22-8P
 433938-31-9P 433938-32-0P 631916-71-7P
 631916-72-8P 631916-73-9P 631916-74-0P
 631916-75-1P 631916-76-2P 631916-77-3P
 631916-79-5P 631916-80-8P 631916-81-9P
 631916-83-1P 631916-85-3P 631916-86-4P
 631916-89-7P 631916-91-1P 631916-92-2P
 631916-93-3P 631916-94-4P 631916-95-5P
 631916-97-7P 631916-98-8P 631917-01-6P
 631917-03-8P 631917-04-9P 631917-05-0P
 631917-06-1P 631917-07-2P 631917-09-4P
 631917-11-8P 631917-13-0P 631917-15-2P
 631917-17-4P 631917-18-5P 631917-19-6P
 631917-20-9P 631917-21-0P 631917-22-1P
 631917-23-2P 631917-24-3P 631917-25-4P
 631917-26-5P 631917-27-6P 631917-28-7P
 631917-29-8P 631917-30-1P 631917-31-2P
 631917-32-3P 631917-33-4P 631917-34-5P
 631917-35-6P 631917-36-7P 631917-37-8P
 631917-39-0P 631917-40-3P 631917-42-5P
 631917-43-6P 631917-44-7P 631917-45-8P
 634151-54-5P 634151-59-0P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and immediate-release formulation of amidine compds. for
 treatment of thrombosis)

RN 433937-73-6 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[[[2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-, (2S)-
 (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-74-7 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-93-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[4-[imino(methoxyamino)methyl]phenyl]methyl-, (2S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 433937-93-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[4-[imino(methoxyamino)methyl]phenyl]methyl-, (2S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 433938-07-9 HCAPLUS

CN 2-Azetidinecarboxamide, N-[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 433938-09-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 433938-21-7 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2,2-difluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.




RN 433938-22-8 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-, (2S)-(CA INDEX NAME)

(CA INDEX NAME)


Absolute stereochemistry.



RN 433938-31-9 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)-2,6-difluorophenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-32-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 631916-71-7 HCAPLUS

Serial No.:10/516,423


CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 3144-16-9

CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).



RN 631916-72-8 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 631916-73-9 HCAPLUS


CN Sulfamic acid, cyclohexyl-, compd. with
(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 100-88-9

CMF C6 H13 N O3 S



RN 631916-74-0 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, phosphate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 631916-75-1 HCAPLUS

CN Phosphoric acid, dimethyl ester, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 813-78-5
CMF C2 H7 O4 P




RN 631916-76-2 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0
CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



RN 631916-77-3 HCAPLUS


CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631916-79-5 HCAPLUS

CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1),

Serial No.:10/516,423


monohydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631916-80-8 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, compd. with 1,2-benzisothiazol-3(2H)-one 1,1-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 81-07-2

CMF C7 H5 N O3 S



RN 631916-81-9 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 631916-83-1 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrochloride (1:1), (2S)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 631916-85-3 HCAPLUS
CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrobromide (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



● HBr


RN 631916-86-4 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, sulfate (2:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 631916-89-7 HCAPLUS
 CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 5872-08-2

CMF C10 H16 O4 S



RN 631916-91-1 HCAPLUS


CN Ethanesulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 594-45-6

CMF C2 H6 O3 S



RN 631916-92-2 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 7697-37-2

CMF H N O3



RN 631916-93-3 HCAPLUS


CN Benzenesulfonic acid, 2,5-dimethyl-, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 609-54-1

CMF C8 H10 O3 S



RN 631916-94-4 HCAPLUS


CN Benzenesulfonic acid, 2,4,6-trimethyl-, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 3453-83-6

CMF C9 H12 O3 S



RN 631916-95-5 HCAPLUS


CN 1,5-Napthalenedisulfonic acid, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:2)
 (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 81-04-9

CMF C10 H8 O6 S2



RN 631916-97-7 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-
 hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-,


benzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



RN 631916-98-8 HCAPLUS


CN D-Glutamic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 6893-26-1

CMF C5 H9 N O4

Absolute stereochemistry.



RN 631917-01-6 HCAPLUS


CN L-Glutamic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-86-0

CMF C5 H9 N O4

Absolute stereochemistry.



RN 631917-03-8 HCAPLUS


CN Glutamic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 617-65-2

CMF C5 H9 N O4



RN 631917-04-9 HCAPLUS


CN L-Arginine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 631917-05-0 HCAPLUS


CN Glycine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[(methoxyamino)imino]methyl]phenyl]methyl-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 56-40-6

CMF C2 H5 N O2



RN 631917-06-1 HCAPLUS


CN Benzoic acid, 2-hydroxy-, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 69-72-7

CMF C7 H6 O3



RN 631917-07-2 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-
 (difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-,
 (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 631917-09-4 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 631917-11-8 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 77-92-9

CMF C6 H8 O7


Absolute stereochemistry.



CM 2

CRN 6915-15-7

CMF C4 H6 O5



RN 631917-17-4 HCAPLUS


CN D-Gluconic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.




CM 2

CRN 526-95-4

CMF C6 H12 O7

Absolute stereochemistry.



RN 631917-18-5 HCAPLUS


CN 1-Propanesulfonic acid, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 5284-66-2

CMF C3 H8 O3 S



RN 631917-19-6 HCAPLUS


CN 1-Butanesulfonic acid, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-
 [imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
 (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5


Absolute stereochemistry.



CM 2

CRN 2386-47-2

CMF C4 H10 O3 S



RN 631917-20-9 HCAPLUS


CN Ethanesulfonic acid, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[(imino(methoxyamino)methyl]phenyl)methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 594-45-6

CMF C2 H6 O3 S



RN 631917-21-0 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]methyl]-, (2S)-, benzenesulfonate (1:1)
(CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 631917-22-1 HCAPLUS
 CN Sulfamic acid, cyclohexyl-, compd. with
 (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-
 difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-
 azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 433938-32-0
 CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 100-88-9
 CMF C6 H13 N O3 S




RN 631917-23-2 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-
 hydroxyacetyl]-N-[[2,6-difluoro-4-
 [imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, sulfate (1:1) (CA
 INDEX NAME)

CM 1

CRN 433938-32-0
 CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-93-9


CMF H2 O4 S



RN 631917-24-3 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrobromide (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



● HBr

RN 631917-25-4 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



RN 631917-26-5 HCAPLUS


CN 2-Naphthalenesulfonic acid, (2S)-compd. with
 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 120-18-3

CMF C10 H8 O3 S



RN 631917-27-6 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, sulfate (2:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 631917-28-7 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-

Serial No.:10/516,423


hydroxyacetyl]-N-[[2,6-difluoro-4-
[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, methanesulfonate (1:1)
(CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 631917-29-8 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7697-37-2


CMF H N O3



RN 631917-30-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, hydrochloride (1:1), (2S)-(CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 631917-31-2 HCAPLUS

CN 1,2-Ethanedithiolonic acid, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:2) (CA INDEX NAME)

CM 1


CRN 433938-32-0
 CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 110-04-3
 CMF C2 H6 O6 S2




RN 631917-32-3 HCAPLUS
 CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0
 CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 3144-16-9
CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).




RN 631917-33-4 HCAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0
CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 5872-08-2
CMF C10 H16 O4 S



RN 631917-34-5 HCAPLUS

Serial No.:10/516,423


CN Benzenesulfonic acid, 2,5-dimethyl-, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-
difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-
azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 609-54-1

CMF C8 H10 O3 S



RN 631917-35-6 HCAPLUS


CN Benzenesulfonic acid, 2,4,6-trimethyl-, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-
difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-
azetidinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 3453-83-6

CMF C9 H12 O3 S



RN 631917-36-7 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, compd. with 1,2-benzisothiazol-3(2H)-one 1,1-dioxide (1:1) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5


Absolute stereochemistry.



CM 2

CRN 81-07-2

CMF C7 H5 N O3 S



RN 631917-37-8 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 631917-39-0 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, phosphate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 7664-38-2

CMF H3 O4 P



RN 631917-40-3 HCAPLUS


CN D-Glutamic acid, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 6893-26-1

CMF C5 H9 N O4

Absolute stereochemistry.



RN 631917-42-5 HCAPLUS


CN L-Arginine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 631917-43-6 HCAPLUS


CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631917-44-7 HCAPLUS


CN L-Lysine, compd. with (2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:1), monohydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 631917-45-8 HCAPLUS


CN 1,5-Naphthalenedisulfonic acid, (2S)-compd. with
1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-(imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:2) (CA INDEX NAME)

CM 1

CRN 433938-32-0

CMF C22 H21 Cl F4 N4 O5

Absolute stereochemistry.



CM 2

CRN 81-04-9


CMF C10 H8 O6 S2



RN 634151-54-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[(hydroxyamino)iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 634151-59-0 HCAPLUS


CN 1,2-Ethanedithiolonic acid, (2S)-compd. with 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(imino(methoxyamino)methyl]phenyl]methyl]-2-azetidinecarboxamide (1:2) (CA INDEX NAME)

CM 1

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



CM 2

CRN 110-04-3

CMF C2 H6 O6 S2



IT 433938-43-3P 433939-57-2P 433939-99-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and immediate-release formulation of amidine compds. for treatment of thrombosis)

RN 433938-43-3 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



-Cl


RN 433939-57-2 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(2,2-difluoroethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 433939-99-2 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]-3,5-difluorophenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

-Cl

IT 433937-75-8P 433938-08-0P 634151-60-3P
 634151-61-4P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and immediate-release formulation of amidine compds. for treatment of thrombosis)
 RN 433937-75-8 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)
 CM 1
 CRN 433937-74-7
 CMF C21 H21 Cl F2 N4 O4

Absolute stereochemistry.



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 433938-08-0 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-

Serial No.:10/516,423


[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl-, (2S)-,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-07-9

CMF C22 H24 Cl F N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 634151-60-3 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)-2,6-difluorophenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, acetate (1:1), (2S)- (CA INDEX NAME)

CM 1

CRN 433938-31-9

CMF C21 H19 Cl F4 N4 O4

Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2



RN 634151-61-4 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, acetate (1:1), (2S)- (CA INDEX NAME)

CM 1

CRN 433937-74-7

CMF C21 H21 Cl F2 N4 O4

Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 9 OF 16 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 9
 ACCESSION NUMBER: 2003:5810 HCAPLUS Full-text
 DOCUMENT NUMBER: 138:78457
 TITLE: Oral pharmaceutical formulations containing
 ι-carrageenan and gelling polymers
 INVENTOR(S): Gaik-Lim Khoo, Cynthia; Gustafsson, Helena
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
 SOURCE: PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000293	A1	20030103	WO 2002-SE1217	20020619
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2450449	A1	20030103	CA 2002-2450449	20020619
AU 2002345463	A1	20030108	AU 2002-345463	20020619
AU 2002345463	B2	20070830		
EP 1401502	A1	20040331	EP 2002-744027	20020619
EP 1401502	B1	20051228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200400028	A	20040415	EE 2004-28	20020619
BR 2002010489	A	20040622	BR 2002-10489	20020619
CN 1518462	A	20040804	CN 2002-812534	20020619
HU 2004000850	A2	20040830	HU 2004-850	20020619
JP 2005501024	T	20050113	JP 2003-506935	20020619
NZ 530086	A	20050930	NZ 2002-530086	20020619
AT 314093	T	20060115	AT 2002-744027	20020619
ES 2254699	T3	20060616	ES 2002-744027	20020619
RU 2323006	C2	20080427	RU 2003-136155	20020619
SK 286238	B6	20080606	SK 2003-1591	20020619
CZ 299859	B6	20081217	CZ 2003-3491	20020619
IL 159217	A	20090211	IL 2002-159217	20020619
IN 2003MN01087	A	20051021	IN 2003-MN1087	20031127
ZA 2003009316	A	20050228	ZA 2003-9316	20031128
MX 2003011546	A	20040319	MX 2003-11546	20031211
BG 108516	A	20041230	BG 2004-108516	20040106
US 20040242536	A1	20041202	US 2004-481232	20040723
PRIORITY APPLN. INFO.:			SE 2001-2069	A 20010621

Serial No.:10/516,423

SE 2001-4049	A	20011130
SE 2002-1660	A	20020531
WO 2002-SE1217	W	20020619

ED Entered STN: 05 Jan 2003

AB An oral pharmaceutical formulation comprising ι-carrageenan, one or more neutral gelling polymers and a basic pharmaceutical inhibits the release of the active ingredient from the formulation at acidic pH. A process for the manufacture of the formulation and the use of the formulations are also disclosed. Tablets were obtained by the direct compression of H 376/95 (basic drug) 50.5, PEG 160.0, ι-carrageenan 40.0, and sodium stearyl fumarate 2.5 mg. The release of H376/95 from blends with varying composition ratios of PEG and ι-carrageenan was determined. Blending different ratios of the anionic polymer, ι-carrageenan and the neutral gelling polymer PEG, the release rate in media with different pH can be modified.

IT 433937-77-0P 433938-43-3P 479621-07-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(in amine-containing azetidine preparation; oral pharmaceutical formulations

containing ι-carrageenan and gelling polymers and basic drugs)

RN 433937-77-0 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-43-3 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


Cl

RN 479621-07-3 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]-2,6-difluorophenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Cl


IT 433937-93-0P 433938-09-1P 433938-22-8P
 479621-12-0P 479621-13-1P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (oral pharmaceutical formulations containing ι-carrageenan and gelling polymers and basic drugs)
 RN 433937-93-0 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.




RN 433938-09-1 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 433938-22-8 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-, (2S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 479621-12-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[(3,5-difluoro-4-imino(methoxyamino)methyl)phenyl]methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 479621-13-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(fluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

13

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 10

ACCESSION NUMBER: 2002:428874 HCAPLUS [Full-text](#)

Serial No.:10/516,423

DOCUMENT NUMBER: 137:20289
 TITLE: New mandelic acid derivatives and their use as thrombin inhibitors
 INVENTOR(S): Inghardt, Tord; Johansson, Anders; Svensson, Arne
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
 SOURCE: PCT Int. Appl., 204 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002044145	A1	20020606	WO 2001-SE2657	20011130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2436220	A1	20020606	CA 2001-2436220	20011130
AU 2002018618	A	20020611	AU 2002-18618	20011130
EE 200300259	A	20030815	EE 2003-259	20011130
BR 2001015861	A	20030923	BR 2001-15861	20011130
EP 1347955	A1	20031001	EP 2001-998535	20011130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002487	A2	20031128	HU 2003-2487	20011130
JP 2004520290	T	20040708	JP 2002-546515	20011130
JP 4177101	B2	20081105		
NZ 526205	A	20050429	NZ 2001-526205	20011130
CN 1291975	C	20061227	CN 2001-822316	20011130
CN 1939902	A	20070404	CN 2006-10143376	20011130
CN 1939903	A	20070404	CN 2006-10143381	20011130
RU 2300521	C2	20070610	RU 2003-115420	20011130
CA 2456426	A1	20030306	CA 2002-2456426	20020830
WO 2003018551	A1	20030306	WO 2002-SE1557	20020830
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002324410	A1	20030310	AU 2002-324410	20020830
AU 2002324410	B2	20080424		
EP 1423362	A1	20040602	EP 2002-759050	20020830
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011847	A	20040908	BR 2002-11847	20020830
CN 1549808	A	20041124	CN 2002-816924	20020830
CN 1301969	C	20070228		
HU 2004001189	A2	20041228	HU 2004-1189	20020830


Serial No.:10/516,423

JP 2005504057	T	20050210	JP 2003-523215	20020830
NZ 531109	A	20060331	NZ 2002-531109	20020830
RU 2341516	C2	20081220	RU 2004-103625	20020830
TW 264434	B	20061021	TW 2002-91132920	20021108
ZA 2003003830	A	20040816	ZA 2003-3830	20030516
BG 107825	A	20040227	BG 2003-107825	20030519
IN 2003DN00780	A	20090227	IN 2003-DN780	20030520
US 20040019033	A1	20040129	US 2003-432411	20030521
US 7129233	B2	20061031		
MX 2003004794	A	20030910	MX 2003-4794	20030529
NO 325228	B1	20080303	NO 2003-2465	20030530
ZA 2004001083	A	20050510	ZA 2004-1083	20040210
IN 2004MN00099	A	20060203	IN 2004-MN99	20040210
NO 326496	B1	20081215	NO 2004-813	20040224
MX 2004001825	A	20040708	MX 2004-1825	20040226
US 20040242492	A1	20041202	US 2004-487805	20040226
US 7056907	B2	20060606		
US 20070202174	A1	20070830	US 2006-520063	20060913
US 20070218136	A1	20070920	US 2006-520052	20060913
IN 2006DN07847	A	20070824	IN 2006-DN7847	20061222
IN 2006DN07848	A	20070824	IN 2006-DN7848	20061222
US 20080090800	A1	20080417	US 2007-797656	20070504
AU 2007203509	A1	20070816	AU 2007-203509	20070727
AU 2007203520	A1	20070816	AU 2007-203520	20070727
JP 2008138009	A	20080619	JP 2008-6611	20080116
JP 2008156362	A	20080710	JP 2008-6608	20080116
KR 2008059681	A	20080630	KR 2008-714404	20080613
KR 2008064204	A	20080708	KR 2008-714402	20080613
KR 2009023745	A	20090305	KR 2009-702806	20090211
PRIORITY APPLN. INFO.:		SE 2000-4458	A	20001201
		SE 2001-965	A	20010319
		SE 2001-1239	A	20010406
		SE 2001-2921	A	20010830
		TW 2001-90129207	A	20011126
		CN 2001-822316	A3	20011130
		JP 2002-546515	A3	20011130
		WO 2001-SE2657	W	20011130
		WO 2002-SE1557	W	20020830
		IN 2003-DN780	A3	20030520
		US 2003-432411	A3	20030521
		KR 2003-707353	A3	20030531
		US 2006-520063	A1	20060913
		KR 2008-714402	A3	20080613

OTHER SOURCE(S): MARPAT 137:20289

ED Entered STN: 07 Jun 2002

GI



II

AB Mandelic acid derivs. I [R = substituted Ph; R1 = OH, CH2OH; X = C6H4, (di)azaphenylene; Y = CH2, CH2CH2] and pharmaceutically-acceptable prodrugs thereof, were prep'd for use as competitive inhibitors of trypsin-like proteases, such as thrombin, or as anticoagulants. Thus, 3,5-Cl(F2CHO)C6H3CHO was prepared from 3,5-Cl2C6H3OMe and was converted to 3,5-Cl(F2CHO)C6H3CH(OSiMe3)CN which was hydrolyzed and resolved with lipase to give (R)-3,5-Cl(F2CHO)C6H3CH(OH)CO2H. This acid was used to acylate the azetidine fragment and deblocked to give the amide (R)-II which had an IC50 <0.02 μ M in the thrombin clotting time test.

IT 433937-72-5P 433937-73-6P 433937-74-7P
433937-75-8P 433937-76-9P 433937-77-0P
433937-78-1P 433937-79-2P 433937-80-5P
433937-81-6P 433937-93-0P 433937-98-5P
433937-99-6P 433938-00-2P 433938-01-3P
433938-02-4P 433938-03-5P 433938-04-6P
433938-05-7P 433938-06-8P 433938-07-9P
433938-08-0P 433938-09-1P 433938-10-4P
433938-11-5P 433938-12-6P 433938-13-7P
433938-14-8P 433938-15-9P 433938-16-0P
433938-17-1P 433938-18-2P 433938-19-3P
433938-20-6P 433938-21-7P 433938-30-8P
433938-31-9P 433938-32-0P 433938-33-1P
433938-35-3P 433938-36-4P 433938-37-5P
433938-51-3P 433938-52-4P 433938-53-5P
433938-54-6P 433938-55-7P 433938-56-8P
433938-57-9P 433938-58-0P 433938-59-1P
433938-60-4P 433938-61-5P 433938-62-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of mandeloylazetidinecarboxamides as thrombin inhibitors)

RN 433937-72-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[4-[(cyclobutyloxy)amino]iminomethyl]phenyl]methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-73-6 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-74-7 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433937-75-8 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, (CA INDEX NAME)


2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-74-7

CMF C21 H21 Cl F2 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433937-76-9 HCAPLUS


CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433937-77-0 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 433937-78-1 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433937-79-2 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-78-1
 CMF C21 H20 Cl F3 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433937-80-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-81-6 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino[(5-methyl-3-isoxazolyl)methoxy]amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-93-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-98-5 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2,2,2-trifluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433937-99-6 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2,2,2-trifluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433937-98-5

CMF C22 H22 Cl F3 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-00-2 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2,2,2-trifluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-01-3 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-

Serial No.:10/516,423

[3-chloro-5-(2,2-difluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-02-4 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2,2-difluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-01-3

CMF C22 H23 Cl F2 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-03-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2,2-difluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-04-6 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(fluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-05-7 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(fluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-04-6

CMF C21 H22 Cl F N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-06-8 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(fluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-(imino(methoxyamino)methyl)phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-07-9 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-08-0 HCAPLUS
 CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-07-9
 CMF C22 H24 Cl F N4 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 433938-09-1 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-10-4 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-11-5 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-10-4

CMF C23 H25 Cl F2 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-12-6 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]-2-hydroxyacetyl]-N-[[4-(imino(methoxyamino)methyl)phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-13-7 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-(difluoromethoxy)-5-fluorophenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-14-8 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-(difluoromethoxy)-5-fluorophenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-13-7

CMF C21 H21 F3 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-15-9 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-(difluoromethoxy)-5-fluorophenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-16-0 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-bromo-5-(fluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-17-1 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-bromo-5-(fluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-16-0

CMF C21 H22 Br F N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-18-2 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-bromo-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-19-3 HCAPLUS


CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-bromo-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433938-18-2

CMF C21 H21 Br F2 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 433938-20-6 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-bromo-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(imino(methoxyamino)methyl]phenyl)methyl]-, (2S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 433938-21-7 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2,2-difluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(hydroxyamino)iminomethyl]phenyl)methyl]-, (2S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 433938-30-8 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)-3-fluorophenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-31-9 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)-2,6-difluorophenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-32-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-33-1 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)-2,5-difluorophenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-35-3 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-(ethoxyamino)iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-36-4 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(propoxyamino)methyl]phenyl]methyl]-, (2S)-

(CA INDEX NAME)


Absolute stereochemistry.



RN 433938-37-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(1-methylethoxy)amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-51-3 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(3-pyridinylmethoxy)amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-52-4 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(2-methylpropoxy)amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-53-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(ethoxyamino)iminomethyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-54-6 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(phenylmethoxy)amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-55-7 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[4-[(cyclohexyloxy)amino]iminomethyl]phenyl)methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433938-56-8 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[4-[(cyclobutyloxy)amino]iminomethyl]phenyl)methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-57-9 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[4-[[imino[2-[3-(trifluoromethyl)phenoxy]ethoxy]amino]methyl]phenyl)methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-58-0 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-[[[(4-chlorophenyl)methoxy]amino]iminomethyl]phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-59-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[[imino[(3-methoxyphenyl)methoxy]amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-60-4 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-[[[(2-bromophenyl)methoxy]amino]iminomethyl]phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-61-5 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino[[4-methylphenyl)methoxy]amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-62-6 HCAPLUS


CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(trifluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino[(1-propylbutoxy)amino]methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 433938-43-3P 433938-50-2P 433938-88-6P
 433938-96-6P 433939-08-3P 433939-18-5P
 433939-26-5P 433939-38-9P 433939-47-0P
 433939-55-0P 433939-57-2P 433939-58-3P
 433939-99-2P 433940-15-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of mandeloylazetidinedicarboxamides as thrombin inhibitors)
 RN 433938-43-3 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-
 (difluoromethoxy)phenyl]hydroxyacetyl]-2-
 azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-,
 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B


—Cl

RN 433938-50-2 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-
 (trifluoromethoxy)phenyl]hydroxyacetyl]-2-

Serial No.:10/516,423

azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-,
2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—Cl

RN 433938-88-6 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(2,2,2-trifluoroethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



—Cl

RN 433938-96-6 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(2,2-difluoroethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



—Cl

RN 433939-08-3 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(fluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—Cl

RN 433939-18-5 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(2-fluoroethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—Cl

RN 433939-26-5 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—Cl

RN 433939-38-9 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-(difluoromethoxy)-5-fluorophenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—F

RN 433939-47-0 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-bromo-5-(fluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—Br

RN 433939-55-0 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-bromo-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

Br

RN 433939-57-2 HCAPLUS
 CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(2,2-difluoroethoxy)phenyl]hydroxyacetyl]-2-azetidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433939-58-3 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(2-fluoroethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433939-99-2 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]-3,5-difluorophenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B


—Cl

RN 433940-15-9 HCAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(2R)-[3-chloro-5-(difluoromethoxy)phenyl]hydroxyacetyl]-2-azetidiny]carbonyl]amino]methyl]-2,5-difluorophenyl]iminomethyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA

INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—Cl


IT 433938-22-8P 433938-34-2P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of mandeloylazetidinecarboxamides as thrombin inhibitors)
 RN 433938-22-8 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[4-[(hydroxyamino)iminomethyl]phenyl]methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433938-34-2 HCAPLUS
 CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[2,5-difluoro-4-[(imino(methoxyamino)methyl]phenyl]methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:1369750 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 149:548920
 TITLE: Combination antithrombotic therapy with a sulfonyleurea compound acting as a platelet ADP receptor inhibitor
 INVENTOR(S): Conley, Pamela B.; Andre, Patrick; Sinha, Uma
 PATENT ASSIGNEE(S): Portola Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 81pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008137787	A2	20081113	WO 2008-US62561	20080502
WO 2008137787	A3	20090205		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA US 20080279845 A1 20081113 US 2008-114706 20080502 PRIORITY APPLN. INFO.: US 2007-915649P P 20070502 US 2007-915911P P 20070503 US 2007-947921P P 20070703 US 2007-978700P P 20071009				

OTHER SOURCE(S): CASREACT 149:548920
 ED Entered STN: 14 Nov 2008
 AB The invention discloses pharmaceutical compns. and methods of using combination therapies containing [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonyleurea

(preparation included), or a pharmaceutically acceptable salt thereof, for the treatment of thrombosis diseases.

IT 433937-93-0, AZD 0837 1079152-20-7


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination antithrombotic therapy with sulfonylurea compound platelet ADP receptor inhibitor)

RN 433937-93-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.




RN 1079152-20-7 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-, mixt. with 5-chloro-N-[[[4-[6-fluoro-1,4-dihydro-7-(methylamino)-2,4-dioxo-3(2H)-quinazolinyl]phenyl]amino]carbonyl]-2-thiophenesulfonamide (CA INDEX NAME)

CM 1

CRN 936500-94-6

CMF C20 H15 Cl F N5 O5 S2




CM 2

CRN 433937-93-0

CMF C22 H23 Cl F2 N4 O5

Absolute stereochemistry.



L21 ANSWER 12 OF 16 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:1300783 HCAPLUS Full-text
 DOCUMENT NUMBER: 149:534068
 TITLE: Quinoline-carboxamide derivatives as P2Y12 antagonists and their preparation, pharmaceutical compositions and use in the treatment of cardiovascular diseases
 INVENTOR(S): Nazare, Marc; Zech, Gernot; Just, Melitta; Weiss, Tilo; Hessler, Gerhard; Czech, Joerg
 PATENT ASSIGNEE(S): Sanofi-Aventis, Fr.
 SOURCE: PCT Int. Appl., 406pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008128647	A1	20081030	WO 2008-EP2790	20080409
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: EP 2007-8209 A 20070423
 OTHER SOURCE(S): MARPAT 149:534068
 ED Entered SIN: 30 Oct 2008
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. of the formula I, which are pharmacol. active compds. Compds. of formula I wherein ring E is a (un)substituted 3- to 10-membered heterocyclic ring; X is N and CR8; B, and Q are independently a covalent bond, C2-10 alkenyl, C2-10 alkynyl, C0-4 alkylene-CH(OH)-C0-4

alkylene, etc.; J is H, (un)substituted C1-4 alkyl; C0-4 alkylene-OCH₂-C1-3 fluoroalkylene-CH₂O-C1-4 alkyl, etc.; R1 is H, (un)substituted C1-4 alkyl, C1-3 alkylene-CONH₂ and derivs. and C1-3 alkylene-CO₂H and derivs.; R₂, R₃, R₄, R₅ R₆ and R₈ are independently H, (un)substituted C1-6 alkyl, C0-4 alkylene-OH and derivs., halo, C1-4 fluoroalkyl, etc.; Z is C0-8 alkylene., C2-10 alkenylene, C2-10 alkynylene, etc.; A is a covalent bond, C3-8 alkylene, C3-8 cycloalkylene and C3-15 heterocyclyl; V is (un)substituted (mono/bi)cyclic 3- to 15-membered (amino)heterocyclic ring; M is H, C1-8 (un)substituted alkyl, CO₂H and derivs., C1-8 alkylene-NH₂ and derivs., CONH₂ and derivs., etc.; and all stereoisomeric forms and mixts. thereof, and physiol. tolerable salts thereof, are claimed. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenosis. They are reversible antagonists of the platelet ADP receptor P2Y₁₂, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y₁₂ is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y₁₂ is intended. The invention furthermore relates to processes for the preparation of compds. of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preps. comprising them. Example compound II•TFA was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their P2Y₁₂ antagonistic activity. From the assay, it was determined that compound II exhibited IC₅₀ value of 0.18 µM.

IT 433937-93-0


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(codrug; preparation of quinolinecarboxamide derivs. as P2Y₁₂ antagonists useful in the treatment of cardiovascular disorders)

RN 433937-93-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1177798 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 147:440330

TITLE: Use of combination of thrombin receptor antagonists and cardiovascular agents for the treatment of cardiovascular disorders


INVENTOR(S): Veltri, Enrico P.; Greenlee, William J.

Serial No.:10/516,423

PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: PCT Int. Appl., 33pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007117621	A1	20071018	WO 2007-US8612	20070405
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2007235353	A1	20071018	AU 2007-235353	20070405
CA 2648613	A1	20071018	CA 2007-2648613	20070405
EP 2001471	A1	20081217	EP 2007-755024	20070405
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
MX 2008012933	A	20081015	MX 2008-12933	20081006
NO 2008004677	A	20081105	NO 2008-4677	20081105
PRIORITY APPLN. INFO.:			US 2006-790469P	P 20060406
			US 2006-808611P	P 20060526
			US 2006-809785P	P 20060531
			US 2006-839474P	P 20060823
			US 2006-839484P	P 20060823
			WO 2007-US8612	W 20070405
ED	Entered STN:	18 Oct 2007		
AB	Disclosed herein are pharmaceutical combinations comprising at least one thrombin receptor antagonist and at least one cardiovascular agent. The thrombin receptor antagonists are statins or antiarrhythmic agents and cardiovascular agents suitable for co-formulation or co-administration with the thrombin receptor antagonist include an endothelin antagonist selected from the group consisting of tezoseptan, bosentan, and sitaxsentan (no data).			
IT	433937-93-0 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (use of combination of thrombin receptor antagonists and cardiovascular agents for treatment of cardiovascular disorders)			
RN	433937-93-0 HCAPLUS			
CN	2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-(CA INDEX NAME)			

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 14 OF 16 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:1150265 HCAPLUS Full-text
 DOCUMENT NUMBER: 147:433639
 TITLE: Composition comprising thrombin receptor antagonist and cardiovascular agent
 INVENTOR(S): Veltri, Enrico P.; Greenlee, William J.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 13pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070238674	A1	20071011	US 2007-696898	20070405
PRIORITY APPLN. INFO.:			US 2006-790469P	P 20060406
			US 2006-808611P	P 20060526
			US 2006-809785P	P 20060531
			US 2006-839474P	P 20060823
			US 2006-839484P	P 20060823
			US 2007-887236P	P 20070130

ED Entered STN: 12 Oct 2007

AB This invention relates to pharmaceutical combinations comprising at least one thrombin receptor antagonist and at least one cardiovascular agent.


IT 433937-93-0, AZD 0837

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (composition comprising thrombin receptor antagonist and cardiovascular agent)

RN 433937-93-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.



L21 ANSWER 15 OF 16 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:802728 HCAPLUS Full-text
 DOCUMENT NUMBER: 141:289066
 TITLE: Use of low-molecular-weight thrombin inhibitors in cholesterol-lowering therapy
 INVENTOR(S): Grind, Margaretha
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082702	A1	20040930	WO 2004-SE417	20040319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004222409	A1	20040930	AU 2004-222409	20040319
AU 2004222409	B2	20070308		
CA 2517191	A1	20040930	CA 2004-2517191	20040319
EP 1608311	A1	20051228	EP 2004-722129	20040319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008522	A	20060307	BR 2004-8522	20040319
CN 1761479	A	20060419	CN 2004-80007286	20040319
JP 2006520813	T	20060914	JP 2006-507972	20040319
NO 2005004285	A	20051020	NO 2005-4285	20050916
ZA 2005007614	A	20060628	ZA 2005-7614	20050920
US 20060183692	A1	20060817	US 2005-550154	20050920
PRIORITY APPLN. INFO.:			GB 2003-6615	A 20030322
			WO 2004-SE417	A 20040319

OTHER SOURCE(S): MARPAT 141:289066
 ED Entered STN: 01 Oct 2004


AB The invention discloses the use of a low-mol.-weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for use in cholesterol-lowering therapy and/or modification of lipid (triglyceride), lipoprotein, and apolipoprotein profiles associated with an increased risk of cardiovascular complications.

IT 433937-74-7 433937-93-0 433938-07-9
433938-09-1 433938-31-9 433938-32-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(low-mol.-weight thrombin inhibitors in cholesterol-lowering therapy)

RN 433937-74-7 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433937-93-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-07-9 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-09-1 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(2-fluoroethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-31-9 HCAPLUS

CN 2-Azetidinecarboxamide, N-[[4-(aminoiminomethyl)-2,6-difluorophenyl]methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 433938-32-0 HCAPLUS

CN 2-Azetidinecarboxamide, 1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[2,6-difluoro-4-[imino(methoxyamino)methyl]phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 16 OF 16 WPIX COPYRIGHT 2009 THOMSON REUTERS on STN
 ACCESSION NUMBER: 2003-402841 [38] WPIX
 CROSS REFERENCE: 2002-599409; 2001-434941
 DOC. NO. CPI: C2003-107107 [38]
 TITLE: New N-(4-amidino-2,6-difluorobenzyl)-1-(2-(3-chloro-5-difluoromethoxyphenyl)-2-hydroxyacetyl)-2-azetidinecarboxamide compounds useful as thrombin inhibitors
 DERWENT CLASS: B03
 INVENTOR: INGHARDT T; JOHANSSON A; SVENSSON A; ANDERS J; ARNE S; TORD I
 PATENT ASSIGNEE: (ASTR-C) ASTRAZENECA AB; (INGH-I) INGHARDT T; (JOHA-I) JOHANSSON A; (SVEN-I) SVENSSON A
 COUNTRY COUNT: 100

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2003018551	A1	20030306	(200338)*	EN	67[0]	
EP 1423362	A1	20040602	(200436)	EN		
KR 2004029091	A	20040403	(200451)	KO		
AU 2002324410	A1	20030310	(200452)	EN		
BR 2002011847	A	20040908	(200462)	PT		
US 20040242492	A1	20041202	(200480)	EN		
HU 2004001189	A2	20041228	(200506)	HU		
JP 2005504057	W	20050210	(200511)	JA	103	
CN 1549808	A	20041124	(200516)	ZH		
MX 2004001825	A1	20040701	(200545)	ES		
ZA 2004001083	A	20050727	(200560)#	EN	76	
NZ 531109	A	20060331	(200626)	EN		
US 7056907	B2	20060606	(200638)	EN		
CN 1301969	C	20070228	(200749)	ZH		
MX 247328	B	20070718	(200856)	ES		
AU 2002324410	B2	20080424	(200858)	EN		
NO 326496	B1	20081215	(200919)	NO		
RU 2341516	C2	20081220	(200919)	RU		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003018551	A1	WO 2002-SE1557	20020830
AU 2002324410	A1	AU 2002-324410	20020830
AU 2002324410	B2	AU 2002-324410	20020830
BR 2002011847	A	BR 2002-11847	20020830
CN 1549808	A	CN 2002-816924	20020830
CN 1301969	C	CN 2002-816924	20020830
EP 1423362	A1	EP 2002-759050	20020830
NZ 531109	A	NZ 2002-531109	20020830
EP 1423362	A1 PCT Application	WO 2002-SE1557	20020830
BR 2002011847	A PCT Application	WO 2002-SE1557	20020830
US 20040242492	A1 PCT Application	WO 2002-SE1557	20020830
HU 2004001189	A2 PCT Application	WO 2002-SE1557	20020830
JP 2005504057	W PCT Application	WO 2002-SE1557	20020830
MX 2004001825	A1 PCT Application	WO 2002-SE1557	20020830
NZ 531109	A PCT Application	WO 2002-SE1557	20020830
US 7056907	B2 PCT Application	WO 2002-SE1557	20020830
MX 247328	B PCT Application	WO 2002-SE1557	20020830
JP 2005504057	W	JP 2003-523215	20020830
HU 2004001189	A2	HU 2004-1189	20020830
ZA 2004001083	A	ZA 2004-1083	20040210
MX 2004001825	A1	MX 2004-1825	20040226
MX 247328	B	MX 2004-1825	20040226
US 20040242492	A1	US 2004-487805	20040226
US 7056907	B2	US 2004-487805	20040226
KR 2004029091	A	KR 2004-702939	20040227
NO 326496	B1 PCT Application	WO 2002-SE1557	20020830
RU 2341516	C2 PCT Application	WO 2002-SE1557	20020830
RU 2341516	C2	RU 2004-103625	20020830
NO 326496	B1	NO 2004-813	20040224

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1423362	A1 Based on	WO 2003018551 A
AU 2002324410	A1 Based on	WO 2003018551 A
BR 2002011847	A Based on	WO 2003018551 A
HU 2004001189	A2 Based on	WO 2003018551 A
JP 2005504057	W Based on	WO 2003018551 A
MX 2004001825	A1 Based on	WO 2003018551 A
NZ 531109	A Based on	WO 2003018551 A
US 7056907	B2 Based on	WO 2003018551 A
MX 247328	B Based on	WO 2003018551 A
AU 2002324410	B2 Based on	WO 2003018551 A
NO 326496	B1 Previous Publ	NO 2004000813 A
RU 2341516	C2 Based on	WO 2003018551 A

PRIORITY APPLN. INFO: WO 2001-SE2657 20011130
SE 2001-2921 20010830
SE 2001-2657 20011130
ZA 2004-1083 20040210
WO 2001-SE2 20011130

AB WO 2003018551 A1 UPAB: 20090327
NOVELTY - N-(4-Amidino-2,6-difluorobenzyl)-1-(2-(3-chloro-5-difluoromethoxyphenyl)-2-hydroxyacetyl)-2-azetidinecarboxamide compounds (I) are new.

Serial No.:10/516,423

DETAILED DESCRIPTION - N-(4-amidino-2,6-difluorobenzyl)-1-(2-(3-chloro-5-difluoromethoxyphenyl)-2-hydroxyacetyl)-2-azetidinecarboxamide compounds of formula (I) and their pharmaceutically acceptable derivatives are new.

R1 = H, OR2 or COOR3;

R2 = H, 1-10C alkyl, QAr or QOAr;

Q = 1-3C alkylene optionally interrupted by O;

Ar = aryl optionally substituted by halo, Ph, Me, OMe, halophenyl, halomethyl or halomethoxy; and

R3 = 1-10C alkyl (optionally interrupted by O), QAr or QOAr.

INDEPENDENT CLAIMS are also included for:

(1) a method for treating a condition where thrombin inhibition or anticoagulant therapy is indicated, comprising administering a compound (I); and

(2) preparation of (I).

ACTIVITY - Anticoagulant; Thrombolytic.

MECHANISM OF ACTION - Thrombin inhibitor.


In an assay comprising incubating an inhibitor solution comprising 1-((3-chloro-5-difluoromethoxy-phenyl)-hydroxy-acetyl)-azetidine-2- carboxylic acid 4-carbamimidoyl-2,6-difluoro-benzylamide (Ia) (25 microliters) with plasma for 3 minutes, adding human thrombin in buffer solution (pH 7.4, 25 microliters, 4 NIH units.ml) and measuring the clotting time, (Ia) doubled clotting time with an IC50 of 0.02 microM.

USE - (I) Are useful for treating conditions where thrombin inhibition or anticoagulant therapy is indicated, especially thrombosis and hypercoagulability in blood and tissues (all claimed).

AN.S DCR-691165

CN.S 1-[(3-Chloro-5-difluoromethoxy-phenyl)-hydroxy-acetyl]-azetidine-2-carboxylic acid 4-carbamimidoyl-2,6-difluoro-benzylamide


SDCN RAA2A0



AN.S DCR-709336

CN.S 1-[(3-Chloro-5-difluoromethoxy-phenyl)-hydroxy-acetyl]-azetidine-2-carboxylic acid 2,6-difluoro-4-(N-methoxy-carbamimidoyl)-benzylamide


SDCN RAACW2



AN.S DCR-709337

CN.S 1-[(3-Chloro-5-difluoromethoxy-phenyl)-hydroxy-acetyl]-azetidine-2-carboxylic acid 2,6-difluoro-4-(N-hydroxycarbamimidoyl)-benzylamide

SDCN RAACW3



Search History

```

L1          STRUCTURE UPLOADED
L2          STRUCTURE UPLOADED
L3          8 SEA SSS SAM L2
L4          150 SEA SSS FUL L2
L5          STRUCTURE UPLOADED
L6          8 SEA SUB=L4 SSS SAM L5

FILE 'HCAPLUS' ENTERED AT 14:51:23 ON 22 MAY 2009
L7          15 SEA SPE=ON ABB=ON PLU=ON L4
L8          2 SEA SPE=ON ABB=ON PLU=ON ABRAHMSEN S?/AU
L9          36 SEA SPE=ON ABB=ON PLU=ON INGHARDT T?/AU
L10         136 SEA SPE=ON ABB=ON PLU=ON MAGNUSSON A?/AU
L11          9 SEA SPE=ON ABB=ON PLU=ON SIGFRIDSSON C?/AU
L12          3 SEA SPE=ON ABB=ON PLU=ON THUNE M?/AU
L13          4 SEA SPE=ON ABB=ON PLU=ON (L8 OR L9 OR L10 OR L11 OR L12)
          AND L7

FILE 'WPIX' ENTERED AT 14:53:43 ON 22 MAY 2009
L14          9 SEA SSS SAM L2
L15          80 SEA SSS FUL L2
L16          11 SEA SPE=ON ABB=ON PLU=ON L15/DCR
L17          5 SEA SPE=ON ABB=ON PLU=ON (L8 OR L9 OR L10 OR L11 OR L12)
          AND L16

FILE 'BEILSTEIN' ENTERED AT 14:54:52 ON 22 MAY 2009
L18          0 SEA SPE=ON ABB=ON PLU=ON L4
L19          0 SEA SPE=ON ABB=ON PLU=ON L4

FILE 'HCAPLUS, WPIX' ENTERED AT 14:57:39 ON 22 MAY 2009
L20          5 DUP REM L13 L17 (4 DUPLICATES REMOVED)

FILE 'HCAPLUS, WPIX' ENTERED AT 14:59:09 ON 22 MAY 2009
L21          16 DUP REM L7 L16 (10 DUPLICATES REMOVED)

```